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For nearly a century, heart disease has been the leading source of death and disease in the
United States, causing the deaths of hundreds of thousands of individuals every year and burdening
millions more with diminished health and severe disability. However, despite the significant
known prevalence of heart disease, studies suggest that many more individuals—and particularly
those within the female and elderly populations—may possess undiagnosed heart disease which
remains undetected even after death due to the lack of autopsy examination. In the absence of
autopsy, many cases of heart disease may never be identified, resulting in a skewed understanding
of disease burden which may hinder improvements in diagnosis and treatment of heart disease.
This may also impair accurate detection of high-risk individuals who are unknowingly susceptible
to infectious diseases such as influenza, pneumonia, or—a more current concern—the recently
discovered novel coronavirus-19.

In addition, heart disease often carries strong genetic

components, making it vital that undiagnosed heart disease be identified so that family members
can likewise be made aware of their risk.
In order to identify the prevalence of undocumented heart disease in the absence of autopsy
examination, 50 cadaveric donor hearts were examined, and findings were compared with
documented prevalence according to donor medical records. Results revealed that whereas only
30% possessed documented forms of heart disease, features consistent with mild to severe forms
of heart disease were observed in 98% of donors. Since most of these donors were elderly, this
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suggests that the vast majority of the elderly population likely possesses mild to severe forms of
heart disease. Undocumented heart disease was particularly prevalent in the female population,
with 50% of female donors displaying undocumented features of heart disease in the absence of
any documented form of CVD (heart disease or otherwise), although undocumented heart disease
in the absence of documented CVD was also observed in 36% of male donors.
Since cadaveric tissue has not previously been utilized for gene expression studies, an RNA
extraction protocol was modified for embalmed tissue in order to identify genetic risk factors
potentially associated with these undocumented cases of heart disease. This protocol yielded
amplifiable RNA of sufficient yield and purity for microarray analysis. While the extent of RNA
degradation varied between samples, microarray analysis revealed over 6,000 unique mRNA
transcripts consistently detected in all cadaveric samples, including a wide variety of transcripts
known to be associated with heart disease.
This study is the first to identify the significant prevalence of undocumented heart disease
in cadaveric donors and suggests that many forms of heart disease remain undiagnosed in the
absence of autopsy, particularly in the elderly and female populations. This study is also the first
to utilize embalmed cadaveric tissue for the purpose of gene expression studies. This technique
will potentially provide unprecedented opportunities for genomic studies related to disease
etiology within cadaver donors and allow for the identification of genetic risk factors which may
have been passed on to family members. Collectively, these findings can be utilized to gain a more
accurate understanding of heart disease burden within the population, potentially facilitating the
identification of high-risk individuals and reducing the fatal effects of heart disease in those
unaware of their risk.
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CHAPTER 1

Significance and Applications of Undocumented Heart
Disease in Cadaveric Donors
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Introduction to Global Burden of Cardiovascular Disease
In 1921, heart disease became the leading cause of death (COD) in the United States
(Greenlund et al., 2006). In the nearly one hundred years since then, the number of deaths caused
by heart disease each year has fluctuated, but its status as the number one killer in the US remains
unchanged (Virani et al., 2020).

Heart disease encompasses all cardiovascular conditions

specifically affecting the heart, including coronary heart disease, ischemia heart disease, cardiac
arrhythmias, cardiomyopathies, and congenital heart disease (Virani et al., 2020; Pellicori and
Cleland, 2015). In 2017, heart disease was reported to have collectively caused the deaths of
647,457 individuals, amounting to 23% of all deaths occurring in the US. When peripheral forms
of cardiovascular disease (CVD) such as stroke were taken into account, this percentage rose to
30.5%, making CVD the underlying COD for 859,125 individuals in the United States (Heron
2019) (Figure 1.1A). These staggering numbers are not restricted to the US; CVD is also the
leading COD globally (Naghavi et al., 2017), serving as the underlying factor in approximately
17.8 million deaths each year (Virani et al., 2020), with heart disease specifically causing the
majority of these deaths (Figure 1.1B).
Beyond its role in causing millions of deaths every year, CVD is also a major factor in nonfatal disease burden in the US.

Based on results from the National Health and Nutrition

Examination Survey conducted by the CDC from 2013-2016, it was estimated that approximately
121.5 million adults in the US were living with some form of CVD (Virani et al., 2020). These
results demonstrated that hypertension was by far the most common class of CVD represented in
these individuals, yet even with hypertension and other vascular forms of CVD excluded, reports
from 2018 indicate that approximately 30.3 million adult Americans possess a heart disease
diagnosis (Centers for Disease Control and Prevention, 2018a). This vast CVD burden carries
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Figure 1.1 Leading causes of death in the United States and worldwide.
(A) CVD is the leading COD in the US, annually causing over 850,000 deaths. Heart disease
alone accounts for the majority of these deaths, causing approximately 75% of CVD-related
deaths and serving as the leading COD in the US even with peripheral forms of CVD excluded.
Source: CDC National Center for Health Statistics, 2017 and AHA Heart Disease and Stroke
Statistics—2020 Update.
(B) CVD is also the leading COD worldwide, causing approximately 17.8 million deaths every
year. Heart disease accounts for over 11 million of these deaths, alone resulting in more deaths
than cancer, the second leading COD in the world. Source: World Health Organization Global
Health Estimates, 2016.
3

with it significant costs, both in terms of disease-related disability and years of life lost, as well as
in regards to health care expenditures (Mensah and Brown, 2007; Yazdanyar and Newman, 2009;
Naghavi et al., 2017; Reynolds et al., 2019). While some have suggested that coronary heart
disease-related mortality will decline in the 21st century due to enhanced preventative strategies
(Dalen et al., 2014), others have argued that in spite of the decline in coronary heart disease
following the severe spike in the 1960s, other forms of heart disease are on the rise (Pellicori et
al., 2015; Fajemiroye et al., 2018). Despite decreased incidence of coronary heart disease, reports
assessing health costs from 2014-2015 estimated that the cost of CVD, taking into account both
direct and indirect expenses, was approximately $351.3 billion, and this number is estimated to
more than triple by 2035 (Virani et al., 2020). It is thought that the primary reason for this
anticipated spike in CVD-related health care expenditures is increased longevity within the
population, and the subsequent increase in the percentage of the population made up of elderly
individuals (Yazdanyar et al., 2009; Pellicori et al., 2015; Dharmarajan and Rich, 2017).

Age-specific Prevalence of CVD
The impact of CVD is felt across generations, but the majority of CVD-related deaths occur
in the elderly population (Heron, 2019; Centers for Disease Control and Prevention, 2018b). In
2017, only 10% of deaths were caused by heart disease in individuals aged 25-44, but these
percentages progressively increased in higher age brackets, and values for the elderly revealed that
heart disease causes 25.1% of deaths in individuals aged 65-84 and 28.6% of deaths in individuals
aged 85 and older (Heron, 2019) (Figure 1.2). Furthermore, a report from the Centers for Disease
Control and Prevention (CDC) stated that 80% of all heart disease-related deaths in 2018 occurred
in individuals over the age of 65 (2018b).
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Figure 1.2 Frequency of heart disease-related deaths in the US by age.
Heart disease death rates by age in the US reveal that risk of heart disease-related death
significantly increases with age, with heart disease causing 25% or more of all deaths in
individuals over the age of 65. Source: CDC National Vital Statistics Report, Deaths: Leading
Causes for 2017.
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However, these values only take into account the cases of CVD serving as the underlying
COD in each population. When the full prevalence of diagnosed CVD in each individual age range
is taken into account, the severity of CVD burden becomes much more apparent. Studies have
revealed that while CVD prevalence in young adults is approximately 29.8% and 17.2% in males
and females, respectively, CVD incidence rapidly rises with increasing age.

Over half of

individuals—both male and female—between the ages of 40 and 59 possess CVD, and these values
progressively increase to 77-78% in individuals over the age of 60 and may be as high as 89-91%
in individuals over 80 (Table 1.1). Of note, however, is the fact that the majority of these cases
reflect a diagnosis of hypertension; CVD classes such as heart disease, heart failure, and stroke
without hypertension have been found to be significantly less prevalent in all age groups, but these
conditions still affect ~34% of females and ~43% of males over the age of 80 (Virani et al., 2020).
This immense CVD burden in the elderly population is significant, and as the elderly
population increases, CVD burden will likewise increase, making it critically important to
establish effective CVD treatment and prevention strategies in order to minimize the effects of
CVD-related burden in the years to come.

Potential for Undiagnosed Heart Disease
In order to implement effective strategies for treatment and prevention of CVD, accurate
understanding of disease prevalence and utilization of precise diagnostic methods is critical.
However, certain studies have suggested the possibility that many cases of CVD—and more
specifically, heart disease—have the potential to remain undiagnosed both during the patient’s
lifetime and, in many cases, even after death.
One reason for lack of diagnosis is the fact that certain forms of heart disease display
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Age (years)

20-39

40-59

60-79

80+

Male CVD Prevalence

29.8%

56.9%

77.2%

89.3%

Female CVD Prevalence

17.2%

51.6%

78.2%

91.8%

1.1%

7.5%

25.1%

43.3%

1.4%

8.3%

17.6%

34.3%

Male CVD Prevalence
Without Hypertension
Female CVD Prevalence
Without Hypertension

Table 1.1 Prevalence of CVD in the US by age, with and without hypertension.
Assessment of CVD prevalence in males and females in the US reveal that a significant
proportion of CVD diagnoses are based on hypertension, and that overall prevalence of CVD
increases significantly with age. CVD prevalence with hypertension excluded reveals that nonhypertensive forms of CVD are less prevalent, particularly in younger individuals, but that
incidence of these conditions likewise increases significantly with age. Source: Table modified
from data presented in the American Heart Association Heart Disease and Stroke Statistics—
2020 Update (Verani et al., 2020) based on data from the National Health and Nutrition
Examination Survey, 2013-2016.
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subclinical or atypical features in their early stages and may remain asymptomatic until a major
cardiac event occurs (Quinn et al., 2017; Reynolds et al., 2019). For example, atrial fibrillation, a
common cardiac arrhythmia, has been found to be asymptomatic in approximately one-third of
cases and is often encountered by accident during routine examinations in seemingly healthy
individuals. Despite the lack of symptoms and no apparent impact on quality of life, asymptomatic
atrial fibrillation carries with it the same—albeit unknown—risk as symptomatic atrial fibrillation,
and is associated with increased risk of stroke and heart failure (Savelieva and Camm, 2000).
Furthermore, recent studies assessing myocardial fibrosis by cardiac magnetic resonance
(CMR) in the elderly have demonstrated that asymptomatic patients possessing these hidden
myocardial features were more likely to experience heart failure than those possessing previous
myocardial infarction (Shanbhag et al., 2019; Halliday and Pennell, 2019). This suggests that if
patients are not already identified as possessing myocardial fibrosis via CMR, there would be no
external symptoms indicating predisposition to heart failure until the event had already occurred.
Studies in the same cohort of individuals revealed that unrecognized myocardial infarction is
common in elderly individuals (Schelbert et al., 2012) and additional studies have demonstrated
that silent myocardial infarction is a common autopsy finding in individuals who had experienced
sudden cardiac death, indicating that many myocardial infarctions go undetected, but have severe
and unexpected consequences later in life (Vähätalo et al., 2019).

Likewise, hypertrophic

cardiomyopathy, a typically genetic form of heart disease with a prevalence of 1:500 in the general
population, is asymptomatic in the majority of cases and in many cases, death is the first
manifestation of the disease (Gersh et al., 2011; Marian and Braunwald, 2010).
The prominent presence of comorbidities, particularly in the elderly population, likewise
could inhibit accurate diagnosis of heart disease and obscure accurate representation of heart
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disease burden in the population (Torabi et al., 2009; Fares et al., 2011b). Approximately 25% of
people in the US and 2 out of every 3 individuals in the elderly population possess multiple chronic
conditions (Gill and Moore, 2013). These conditions can make diagnosis of heart disease difficult,
especially if symptoms are generalized and nonspecific (Lien et al., 2002). The presence of these
additional comorbidities makes accurate identification of heart disease all the more important,
though, since studies have demonstrated that multimorbidity in elderly patients possessing CVD
is associated with increased risk of death (Tisminetzky et al., 2016).
Accurate diagnosis is further complicated by the reality that many features and symptoms
of heart disease are considered “typical” of the elderly population. Aging in and of itself is
considered the strongest risk factor for development of CVD due to the natural changes that occur
within the cardiovascular system as a result of aging (Reynolds et al., 2019). Mitral annulus
calcification (Canepa et al., 2016), vascular stiffening (Reynolds et al., 2019), myocyte
hypertrophy (Dharmarajan et al., 2007), ventricular thickening and stiffening (Canepa et al., 2016;
Reynolds et al., 2019), and increased deposition of amyloid, lipofuscin, and interstitial collagen
(Waller, 1988; Dharmarajan et al., 2007; Seki and Fishbein, 2016; Kakimoto et al., 2019) are all
known cardiovascular changes that occur with age. However, while these changes are considered
typical (Waller, 1988), they are nevertheless pathologic, and are known to predispose these
individuals to clinical manifestations of CVD (Dharmarajan et al., 2007; Canepa et al., 2016;
Reynolds et al., 2019). Furthermore, certain external signs, such as shortness of breath on exertion,
are not uncommon within the elderly population, but studies have revealed that many patients
manifesting these symptoms actually possess unrecognized heart failure (van Riet et al., 2014),
lending further difficulty to distinguishing normal aging from heart disease.
Finally, there may also be the potential for undiagnosed CVD specifically in the female
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population due to the fact that standards for detection and treatment of CVD are often based on
male parameters which may not be applicable to the female population (Pfaffenberger et al., 2013;
Mazure and Jones, 2015). While gender-specific differences are noted in overall CVD prevalence
in individuals under the age of 60—reflecting the cardio-protective effect of estrogen in
premenopausal women (Reynolds et al., 2019)—these differences diminish over the age of 60,
with overall CVD prevalence in females even slightly exceeding that of males (Virani et al., 2020).
Heart disease in the elderly is still considered to be significantly more prevalent in the male
population, but mortality rates due to heart disease and other forms of CVD are significantly higher
in elderly females than in males (Virani et al., 2020). It has been suggested that this is due to the
fact that manifestation of the disease in females does not occur until later in life (Sanghavi and
Gulati, 2015; Wenger, 2017).
Therefore, based on the nature of heart disease pathogenesis, there is the potential for heart
disease to remain undiagnosed in the early stages of the disease when treatment would be most
effective. Beyond this, however, further studies have suggested an additional concern regarding
undiagnosed heart disease: the reality that heart disease may remain unknown, not only during a
person’s life, but even after death due to the limited number of autopsies performed in the United
States (Hamza, 2017; Goldman, 2018).

Undiagnosed Disease in the Absence of Autopsy Examination
Current statistics for heart disease are based on medical history and diagnosed cases, but
since certain cases of heart disease could remain undiagnosed due to the factors previously
described, it is possible that individuals could possess undiagnosed heart disease that becomes a
compounding factor in their deaths and perhaps even serve as the underlying COD. Autopsy is
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considered the gold standard for determining the exact cause of death and additional comorbidities,
whether through confirmation of premortem diagnoses or identification of undiagnosed conditions
(Hoyert, 2011; Goldman, 2018; Friberg et al., 2019).

However, current autopsy rates have

progressively declined in the US over the past several decades, dropping from 50% in the 1940s
to 41% in the 1970s, and currently are at a mere 8%, with approximately half of these cases being
forensic autopsies and only about 4% of all hospital deaths receiving an autopsy (Goldman, 2018).
Studies have revealed particularly drastic declines in autopsy rates for females, for deaths due to
disease rather than external causes, and, most significantly, for the elderly population, with less
than 1% of deaths in individuals over the age of 85 years receiving an autopsy (Tai et al., 2001;
Attems et al., 2004; Hoyert, 2011; Friberg et al., 2019).
The cause of this drastic decline in autopsy rates is thought to be related to the arrival of
advanced, non-invasive diagnostic tools which allow for more accurate pre-mortem diagnosis, but
additional reasons include lack of reimbursement, opposition from family members, fear that
autopsy might reveal information warranting malpractice suits, and the assumption that cause of
death is already known and autopsy would not reveal any additional information (Coradazzi et al.,
2003; Aiello et al., 2007; Dehner, 2010; Hamza, 2017; Goldman, 2018; Friberg et al., 2019).
However, current research has demonstrated that these premortem evaluations may be insufficient
for a precise diagnosis of an individual’s cause of death. While medical imaging allows for some
level of diagnosis and detection, these techniques cannot provide the same accuracy and specificity
that is observed through postmortem gross and histologic examination (Shojania and Burton 2008;
Aiello, 2016), and studies have confirmed the insufficiency of medical imaging for conclusive
establishment of accurate COD (Roberts et al., 2003).
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Several decades ago, studies in the US demonstrated that the COD included on a death
certificate was often inaccurate in the absence of autopsy examination, with major disagreements
occurring in 29% of all deaths and minor disagreements regarding specific diseases within a
particular category reported in an additional 26% (Kircher et al., 1985). In the years since then,
the accuracy of COD has improved (Shojania et al., 2003), but studies have demonstrated that
significant discrepancies still persist even today (Kuijpers et al., 2014; Mieno et al., 2016; Euler et
al., 2017). The reported inaccuracy of death certificates in these studies vary, but over the past
two decades, studies have reported discrepancy rates ranging from 4%-56% depending on the
location, setting, and population (Tai et al., 2001; Shojania et al., 2003; Bombi et al., 2003;
Coradazzi et al, 2003; Attems et al., 2004; Nashelsky and Lawrence, 2003; Tavora et al., 2008a;
Tavora et al., 2008b; Fares et al., 2011a; Ioan et al., 2012; Kuijpers et al., 2014; Mieno 2016;
Marshall and Milikowski, 2017). While these studies present a wide range of possible discrepancy
rates, current evaluations of these studies estimate that the rate of discovering significant errors in
COD which would have impacted treatment and survival to be ~10% of autopsies (Marshall et al.,
2017; Goldman, 2018), although higher rates of discrepancy are frequently reported in private
autopsy settings and out-of-hospital deaths (Tavora et al., 2008a; Tavora et al., 2008b), as well as
in the elderly population (Saad et al., 2007).
In addition to detecting inaccuracies in COD, autopsy examination is also important in
identifying additional medical conditions which may have indirectly contributed to an individual’s
death and which could have implications for family members. While rate of detection for major
errors in COD are estimated to be around 10% of autopsied cases (Goldman, 2018), studies have
suggested that the detection of significant unknown medical conditions during autopsy is much
higher.

Many studies have demonstrated that autopsy examination—beyond revealing
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inaccuracies in underlying COD—is a powerful diagnostic tool, with current studies revealing
major unexpected findings in 25%-32% of autopsied cases (Euler et al., 2017; Friberg et al., 2019).
Recent studies in ER patients have also demonstrated that even with advanced diagnostic
techniques like multislice computed tomography—the diagnostic techniques supposed to have
eliminated the necessity for autopsy (Hamza, 2017)—up to 4.1% of potentially fatal diagnoses are
still missed (Euler et al., 2017).

Undiagnosed Cardiovascular Disease in the Absence of Autopsy
A wide range of undiagnosed diseases have been detected through autopsy examination,
but many studies have found that cardiovascular conditions specifically are frequently
misdiagnosed in the absence of autopsy. A study in 2002 assessed data obtained from death
certificates and compared the results with autopsy, discovering that the sensitivity for death
certificates reporting CVD was only 0.28, reflecting 119 undiagnosed cases of CVD compared to
only 46 cases accurately diagnosed. It was found that ischemic heart disease, hypertensive heart
disease, and valvular heart disease were the most frequently underreported classes. While there
were also a small number of false positive reports indicating over-diagnosis of CVD, the overall
results of the study revealed a true prevalence of CVD as COD in 32% of cases, compared to the
reported prevalence of only 16% according to death certificates (Sington and Cottrell, 2002).
In 2006, Ravakhah reported that nearly half of all autopsy-confirmed cases of acute
myocardial infarction were missed in clinical diagnoses, with misdiagnoses more likely to occur
in female and elderly individuals.

While acute MI was the most frequently misdiagnosed

condition, a finding confirmed by more recent studies (Friberg et al., 2019), other forms of CVD
such as pulmonary embolism, cardiomyopathy, aortic aneurysm, endocarditis, and aortic
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dissection were also frequently underdiagnosed. Interestingly, however, certain forms of CVD
such as cardiopulmonary arrest, cardiac arrhythmias, and a small percentage of myocardial
infarctions were inaccurately reported in clinical diagnoses (Ravakhah, 2006). Other studies have
confirmed these variable patterns of over- and under-diagnosis, revealing that CVD conditions
such as coronary artery disease often serve as a “default” diagnosis, sometimes concealing a true
COD which autopsy revealed to be cardiomyopathy, aneurysm, pulmonary embolism, or valvular
disease (Tavora et al., 2008b). An additional meta-analysis of 18 different studies reporting COD
discrepancies determined that CVD was one of the most likely diseases classes to manifest with
discrepant findings between death certificates and autopsy reports (Roulson et al., 2005).
In regards to the elderly population, some studies have reported that increased age is
associated with increased accuracy in reporting MI (Saad et al., 2007; Fares et al., 2011b);
however, analysis of autopsy findings in a geriatric hospital have revealed that the concordance
rate between clinical diagnoses and autopsy diagnoses for heart disease is only 55%, and many
cases of CVD—and heart disease specifically—remain undiagnosed in the absence of autopsy
(Mieno et al., 2016).
Collectively, these studies suggest that many cases of heart disease go undetected in the
absence of a conventional autopsy, but that false positives are also possible, making the true
prevalence of heart disease unclear. However, while certain classes of heart disease seem to be
over-diagnosed, the overall trends observed in autopsy findings indicate that many forms of heart
disease remain hidden in the absence of autopsy, suggesting that the prevalence of heart disease as
an underlying COD may be much higher than what is commonly accepted. Since only 8 percent
of the population receives an autopsy (Hoyert, 2011), there remains 92 percent of individuals whose
stated COD may or may not be accurate or complete. In addition, even if the COD is accurate, it
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is likely that many of these individuals possess undocumented conditions which remain
undiagnosed even after death. Since autopsy rates have been found to be even lower for the elderly
(Friberg et al., 2019) and for women (Blokker et al., 2017; Friberg et al., 2019), it is likely that
discrepant findings and undiagnosed disease could be particularly prevalent in these populations.

Significance of Undiagnosed Heart Disease
Based on these factors, it is possible that many individuals—particularly those within the
elderly and female populations—may possess significant undiagnosed heart disease.

It is

important that this concern be considered and addressed, because the possibility of undiagnosed
heart disease carries with it significant implications, including the potential for health disparities
impacting morbidity and mortality in the female and elderly populations (Attems et al., 2004;
Cook, 2019), the possibility of unknown genetic risk for surviving family members (Tavora et al.,
2008b), and ignorance of increased susceptibility to non-cardiovascular forms of disease
(Corrales-Medina et al., 2010; Clerkin et al., 2020).

Gender-based Health Disparities
In the past, heart disease has commonly been considered a condition that primarily affects
the male population (Wenger, 2017). However, many have suggested that this perception could
be the result of gender-based health disparities surrounding heart disease, where women with these
conditions are simply less likely to be diagnosed and treated because of male-based standards that
do not apply to the female population (McSweeney et al., 2003; Hsich and Piña, 2009; Mazure et
al., 2015).

This is thought to be related to the fact that for many years, women were

underrepresented in clinical trials related to heart disease, resulting in many diagnostic and
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treatment standards based on male parameters which were not perfectly applicable to the female
population (Heiat et al., 2002; Melloni et al., 2010; Mazure et al., 2015). While improvements
have been made in this area, current studies suggest that female subjects may still be
underrepresented in clinical trials related to certain types of heart disease, a factor which evokes
concern regarding whether or not results from these trials can be applied to the population as a
whole (Mazure et al., 2015; Scott et al., 2018).
The reality of this concern was noted over two decades ago by Klodas et al in the context
of aortic regurgitation surgeries where the post-operative mortality rate of women receiving the
surgery was much higher than male mortality rates. This was based on the fact that women would
often not receive the surgical treatment until later stages of the disease. Surgical criteria had been
established in male patients and applied to female patients without adjusting for gender-specific
variations in ventricular size; thus, the male-based parameters were rarely reached in female
patients until their system was in later and more severe stages of the condition. While male patients
were more likely to receive the surgery in response to changes in ventricular size as a preventative
procedure, female patients would typically receive the surgery following manifestation of severe
symptoms since significant changes in ventricular size had not been detected beforehand (1996).
Current studies support this concern, recognizing that female anatomic standards deviate
in certain ways from male standards. Previous studies have indicated that factors such as age,
gender, weight, and height can influence the cardiac chamber size, suggesting that standards for
heart measurements may not be adequate for all people (Pfaffenberger et al., 2013). Heart
measurements for smaller individuals and women may be lower than standards for normal heart
size, making it possible that undiagnosed disease could proceed undetected since it would appear
to fall within normal parameters in its early stages.
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Besides the inadequacy of male anatomic standards for the identification of female disease,
etiology of disease progression has also been found to be markedly different in male and female
patients, making it difficult to identify high risk patients, both in regards to long-term risk as well
as regarding immediate risk of acute cardiovascular events (Cook, 2019). While many risk factors
are similar in males compared with females, females are more likely to develop CVD later in life
and certain risk factors are primarily—and in some cases, only—associated with the female
population (Sanghavi et al., 2015; Wenger, 2017). Current reviews in women’s health recognize
autoimmune disease, gestational diabetes, preeclampsia, psychological symptoms such as
depression and anxiety, chemotherapy, and the combination of oral contraceptives with smoking
as some of the most common risk factors known to strongly predispose females to later
development of CVD (Sanghavi et al., 2015; Wenger, 2017).
In addition to long-term risk factors, presentation of symptoms may also vary between
males and females (Hsich et al., 2009; Cook, 2019). Ischemic heart disease without obstruction to
coronary arteries is more common in females than in males, making it more likely that high risk
patients will be overlooked with standard angiography diagnostic techniques (Chokshi et al.,
2010). Studies have also shown that female patients possessing heart failure are more likely to
display preserved left ventricular function compared with male patients (Lenzen et al., 2008).
Studies assessing symptoms preceding MI in females have also presented unique results, with
certain studies reporting that the classic MI symptom of angina is less commonly observed in
female patients than in males, and that females more typically present with symptoms such as
shortness of breath, fatigue, cold sweat, and dizziness (McSweeney et al., 2003). Other studies
have debated this finding, however, reporting that angina is the most common feature in both male
and female patients (Kreatsoulas et al., 2013; Kreatsoulas et al., 2016), and women were more
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likely to present with additional symptoms such as back pain, facial pain, and palpitations (Hemal
et al., 2016). These conflicting reports demonstrate the variability of heart disease manifestation
within the female population, making it imperative that clinicians and patients alike recognize the
atypical symptoms that may precede cardiac events (McSweeney et al., 2000; Chin et al., 2016).
This is particularly important since some of these symptoms have been found to persist for up to
2 years before the cardiac event occurs (McSweeney et al., 2000), making early intervention very
attainable if symptoms of MI can be recognized as such.
Besides differences in gross features and disease progression, studies have revealed that
underdiagnosis of heart disease in females may also result from a persistent misperception
regarding heart disease as a primarily “male” condition. This mentality fails to recognize the
severe and sometimes even greater risk that the disease poses towards the female population
(Wenger, 2017). Recent surveys within the female population revealed that 45% of the individuals
surveyed were unaware that heart disease was the leading COD for women (Merz et al., 2017);
these statistics make it unlikely that these individuals will consider cardiovascular causation in the
event of abnormal symptom manifestation or recognize this as a significant concern for elderly
female relatives (McSweeney et al., 2000). This misperception may also persist in the clinical
setting, with studies revealing that women are less likely to be referred to a cardiologist than male
patients, even when physical presentation of cardiovascular symptoms is similar, a factor which
was not found to depend on the specific physician providing the referral (Clerc Liaudat et al.,
2018). Studies have also revealed that men are more likely to receive certain types of tests such
as catheterizations than women even when symptom presentations and patient histories were
comparable (Chang et al., 2008) and women are less likely to be evaluated for left ventricular
function, a test important in the diagnosis of heart failure (Lenzen et al., 2008). These studies also
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revealed that women were less likely to be prescribed certain types of drugs for CVD and less
likely to be admitted to cardiology wards (Lenzen et al., 2008).
Collectively, these factors have significant implications for female heart disease patients.
Statistics regarding in-hospital MI-related mortality for male and female patients reveal that female
mortality is significantly higher than in men, although overall heart disease mortality is reported
to be higher in men than in women (Virani et al., 2020). Based on the atypical presentation of
heart disease in females, however, it is possible that the number of females affected by heart
disease may be even higher than what is currently supposed. These findings, coupled with studies
reporting a lower autopsy rate in females than in males (Friberg et al., 2019), suggest that heart
disease may be significantly underdiagnosed in women, resulting in discrepancies regarding the
true burden of heart disease in the elderly female population and placing future generations at
increased risk of heart disease-related morbidity and mortality.

Health Disparities in the Elderly
In addition to health disparities within the female population, undiagnosed heart disease
also carries significant implications for the elderly population. Past studies have observed that
most COD decisions for individuals over the age of 65 are based on pre-mortem diagnoses and are
not confirmed by autopsy (Hoyert, 2011), making it possible that errors may persist, and true
burden of various disease classes in the elderly may remain unknown (Attems et al., 2004).
In order to effectively treat heart disease in an increasing elderly population, it is important
that improvements in management and treatment of heart disease be made, but in order to make
these improvements, accurate data regarding causes of death, manifestations of disease, and
abnormal presentation of disease must be known (Attems et al., 2004; Ioan et al., 2012; Friberg et
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al., 2019). Undiagnosed disease results in inaccurate data related to these conditions and will
potentially inhibit the proper diagnosis and treatment of CVD within the elderly population
(Attems et al., 2004).

Genetic Risk
The possibility of undiagnosed heart disease is also significant because many forms of
heart disease are familial (Keating and Sanguinetti, 1996; Ehret et al., 2011; Pan and Knowles,
2012) and were therefore likely passed on to family members who are unaware of their risk for
developing heart disease. For example, hypertrophic cardiomyopathy (HCM) is inherited in an
autosomal dominant manner and many genetic variants affecting cytoskeletal and sarcomeric
proteins are known to be associated with the development of this condition (Alcalai et al., 2008; Ren
et al., 2018). However, reports have noted that HCM is not frequently observed in cardiology
clinics, suggesting that many cases of HCM remain undiagnosed (Gersh et al., 2011).
Without knowledge of their predisposition towards heart disease, these individuals may
remain ignorant of the disease in its early stages when preventative measures would be most
effective (Miller and Hinton, 2014; Reynolds et al., 2019). Certain surgical procedures are
associated with increased risk of mortality in the elderly population, forcing them to utilize more
conservative—but sometimes less effective—treatments for severe forms of CVD (GonzálezSaldivar et al., 2016; Turrentine et al., 2006). These factors reinforce the necessity of early
detection and treatment in order to most effectively manage and reduce heart disease burden in the
population.
Studies have demonstrated that reduction of CVD risk factors in early years results in lower
risk of developing CVD with age (Lloyd-Jones et al., 2006), despite changes that occur in the aging
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heart which predispose elderly individuals towards CVD (Dhingra and Vasan, 2012). Therefore,
the most successful means of reducing disease burden in the elderly population would be to
minimize CVD risk factors in early years. Due to the strong genetic nature of many forms of heart
disease (Keating et al., 1996; Ehret et al., 2011; Pan et al., 2012) undiagnosed heart disease in the
elderly may often correlate with unknown heart disease risk in younger generations; therefore, in
order to reduce heart disease burden throughout all generations, diagnosis and intervention must
begin with informed identification of risk earlier in life (Lloyd-Jones et al., 2006).

Increased Susceptibility to Infectious Disease
Beyond unknown genetic risk of heart disease for family members, the persistence of
undocumented heart disease in the population is also significant because CVD is known to place
individuals at increased susceptibility to death by infectious disease (Corrales-Medina et al., 2010).
Studies in patients with pneumonia have demonstrated the presence of chronic cardiac disease in
over half of hospitalized individuals over the age of 65 (Fry et al., 2005) and other studies have
demonstrated that infection often triggers the development of cardiac events and arrhythmias,
particularly in individuals possessing pre-existing heart conditions (Musher et al., 2007; CorralesMedina et al., 2012; Corrales-Medina et al., 2013).
An additional threat is that of the recently discovered novel coronavirus-19 (COVID-19),
which has likewise been shown to pose significant risk to those possessing pre-existing heart
conditions.

Numerous reports regarding comorbidities found in COVID-19 patients have

consistently revealed that underlying CVD poses a strong increased risk of infection and mortality
(Guo et al., 2020; Huang et al., 2020; Shi et al., 2020; Wu and McGoogan, 2020; Zheng et al.,
2020; Zhou et al., 2020) with certain studies revealing that up to 25% of individuals requiring ICU
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care possess underlying CVD (Wang et al., 2020). Autopsy studies have confirmed this, with a
study by Schaller et al demonstrating that in post-mortem examination of COVID-19 patients, 8
of the 12 patients examined possessed pre-existing CVD, along with many other comorbidities
which made them significantly more susceptible to the virus (2020).
Therefore, while undiagnosed heart disease may not appear to be a cause for concern if it
does not cause extreme morbidity, noticeable symptoms, or shortened lifespan (Gersh et al., 2011);
nevertheless, the presence of undiagnosed heart disease remains significant. This undiagnosed
disease places the individual’s health in an unstable position, where extreme environmental
stressors such as infection could quickly disrupt the delicate balance between health and disease,
or even between life and death, making it vital that these undiagnosed conditions be made known.

Utilization of Cadaveric Donors for Studying Undocumented Heart Disease
The dangers of undiagnosed heart disease are considerable and have weighty implications
for the health of individuals across generations, both now and in the years to come. However,
lacking in previous studies has been the ability to thoroughly study the prevalence of
undocumented heart disease in individuals representative of the 92% of the population for whom
an autopsy is not administered after death (Goldman, 2018).

Most studies demonstrating

discrepancies in COD have been conducted by retrospectively comparing archived autopsy
reports with clinical diagnoses conducted before death (Mieno et al., 2015; Marshall et al., 2017;
Friberg et al., 2019). It has been argued that the errors revealed through autopsy examination are
due to a selection bias, where the cases referred for autopsy naturally possess a higher likelihood
of yielding discrepant findings due to the fact that the cause of death was ambiguous enough to
warrant autopsy examination (Shojania et al., 2008; Tavora et al., 2008a). If this were the case,
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lower discrepancy rates would be expected in the non-autopsied population. This has not been
confirmed by studies evaluating discrepancy rates at institutions with higher autopsy rates
(Shojania et al., 2003), but it remains a significant question as to whether or not autopsied
individuals are representative of the population as a whole.
Cadaveric donors provide a unique opportunity to assess the true burden of undocumented
heart disease in the population due to the fact that none of these individuals receive an autopsy
before donation.

These individuals possessed a COD that was considered clear and

straightforward enough to be assigned in the absence of autopsy, making them representative of
the remaining 92% of the population who will likewise never receive an autopsy. Had these
individuals not been registered as cadaveric donors, any unknown pathologies they possessed and
any significant information impacting their family members would have been permanently lost,
as might be the case for many individuals in the population who never receive any sort of postmortem examination. Examination of cadaveric donors provides the opportunity to assess
undocumented disease in a sampling of the population for whom no COD-selection bias exists.
In addition to being representative of the portion of the population not receiving an
autopsy, cadaveric donors are also an excellent means of studying the elderly population
specifically. The majority of donors encountered in body donation programs are elderly, with
average ages ranging from 60-83 years old depending on the location studied (Cornwall et al.,
2012; Collins et al., 2018). While this does create a bias towards the elderly population and
inhibits complete transferability of findings to the younger population, the marked predominance
of elderly individuals in anatomical donor programs allows for very specific studies in disease
prevalence and even disease progression in a segment of the population that has been reported to
be under-represented in many clinical trials (Heiat et al., 2002).
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In addition to the unique population demographics represented in cadaveric donors,
further benefits of their utilization in studies of undocumented disease include easy accessibility,
elimination of the need to obtain approval for tissue collection/utilization for scientific studies,
and increased safety (MacBride, 1998). When an individual registers to become an anatomic
donor, the agreement encompasses a wide range of utilization, including education of medical
personnel as well as research purposes (Nicholson et al., 2005). Since there is often opposition
to the use of organs and tissue for scientific research (MacBride, 1998; Aiello et al., 2007), the
open accessibility of these samples for research is a significant benefit of conducting research
with cadaveric donors. Additionally, while certain infectious diseases are still transmissible after
fixation (Demiryürek et al., 2002), the embalming process does reduce infectivity for many
disease agents, eliminating some of the risks associated with human subject research (Creely,
2004).
Lastly, cadaveric research also provides the unique ability to examine body-wide
disorders through extensive dissection and tissue analysis. Cause of death is a multifactorial
process that often involves a complex interaction of different disorders (Torabi et al., 2009), and
multimorbidity is associated with an increased risk of death (Tisminetzky et al., 2016), making it
imperative that COD be understood in the context of other pathologies. Studies have revealed
that while only one disease may be reported as the underlying COD in death certificates, autopsy
examination often reveals multiple causes of death (Sington et al., 2002). By excluding or
overlooking these additional pathologies in COD information, the true burden of disease in the
population remains unknown; cadaveric studies provide the opportunity to examine COD in a
systemic manner, facilitating an accurate understanding of disease burden and interactions
between body systems.
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Limitations of Cadaveric Research
While the benefits of cadaveric research are many and varied, certain limitations exist in
relation to the utilization of cadaveric tissue for scientific studies. Some of the earliest studies
utilizing embalmed cadaveric tissue for research expressed concern regarding the effects of
formalin on tissue structure and integrity, stating that the embalming process prevented tissues
from being utilized for certain avenues of research such as histology due to decreased preservation
of cell structure (MacBride, 1998).
Molecular studies are also difficult to perform with embalmed tissue, because formalin
fixation results in extensive cross-linking between proteins and nucleic acids (Hoffman et al.,
2015). This feature is necessary for the preservation of tissue structure and integrity (Brenner,
2014), but is known to result in significant damage and degradation of genetic material and poor
extraction (Okello et al., 2010; Eltoum et al., 2013). Furthermore, formalin is also an enzyme
inhibitor, a characteristic imperative to its role in preventing tissue degradation and decay
(Canene-Adams, 2013), but which presents an additional difficulty in utilizing formalin-fixed
tissue for genomic studies due to the potential inhibition of proteinase or polymerase enzymes
(Zagga et al., 2013).
In regard to gross identification of pathology, an additional concern involves the
possibility of embalming artifacts in the organs being examined. Studies have demonstrated that
embalming artifacts can resemble pathologies such as aortic dissection and can only be
distinguished by histologic confirmation (Rae et al., 2015).

However, other studies have

demonstrated that for many disease conditions, gross examination does reliably correlate with
pathology and histology in manners similar to those observed in fresh tissue (Rae et al., 2017).
Therefore, rather than negating the utilization of cadaveric donors for research studies, this
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concern merely confirms the necessity of histologic confirmations in pathology-based studies,
particularly for certain diseases.

Current Research Involving Cadaveric Donors
Despite these limitations, however, cadaveric donors have successfully been utilized in
many studies over the past several decades for research involving both gross, histologic, and
molecular analysis. These studies have confirmed the extensive prevalence of pathology—both
diagnosed and undiagnosed—in cadaveric donors (Chun et al., 2007; Wood et al., 2010; Plummer
et al., 2018), and have also established the viability of formalin-fixed tissue for histology
(Nicholson et al., 2005; Rae et al., 2018) and the ability to identify conditions with a potential
genetic basis from formalin-fixed tissue (Gerhard et al., 2016; Gielda and Riggs, 2017).

Histologic Analysis in Cadaveric Donors
While formalin fixation has been suggested to prevent tissue from being utilized for
histologic analysis (MacBride, 1998), more recent studies have demonstrated that cadaveric
samples can be used for reliable histologic confirmation (Nicholson et al., 2005; Wood et al.,
2015; Rae et al., 2018), although the quality of tissue can be affected by factors such as postmortem interval between death and fixation, extent of tissue perfusion, and certain causes of death
(Nicholson et al., 2005; Canene-Adams, 2013; Rae et al., 2018). Nicholson et al analyzed the
histologic quality of cadaveric tissue taken from several organs—including the heart—and
demonstrated that, despite previous concerns regarding poor preservation of cell structure
(MacBride, 1998), cadaver tissue could be utilized for reliable histologic analysis (Nicholson et
al., 2005). This study also demonstrated, and was confirmed by later studies (Rae et al., 2018),
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that COD was not associated with impaired histologic quality in heart tissue, an important factor
to consider when evaluating the potential use of cadaveric hearts for the study and confirmation
of heart disease. Furthermore, it was also shown that quality of tissue was not affected by
prolonged duration between embalming and sectioning, and embalmed tissues remained viable
for histologic analysis for up to 7 years after embalming. Later studies confirmed these findings,
demonstrating that formalin-fixed tissue could be utilized for identification and confirmation of
pathologies correlating with gross observation and medical histories (Wood et al., 2015).
However, based on concerns regarding the limited sample size and questions regarding
reliability of the rating system utilized in certain past studies, Rae et al conducted a comprehensive
analysis of histopathologic reliability of embalmed cadaveric tissue (Rae et al., 2018). Samples
were rated based on specific histologic features and it was concluded that cadaveric tissue was a
reliable source of tissue for research, although certain organs such as the lungs did display reduced
quality compared to certain other organs. Particularly noteworthy was the fact that of the 4 organs
sampled (heart, kidney, liver, and lung), cadaveric hearts possessed the highest percentage of
sections displaying excellent histologic quality. It was suggested that this could be due to the fact
that the heart is closest to the site of fixation and is preserved from both within the heart chambers
and through coronary circulation, ensuring thorough fixation and excellent preservation of tissue
(Rae et al., 2018). This further supports the utilization of cadaveric heart tissue for identification
and confirmation of heart disease.

Pathologic Observations in Cadaveric Donors
There have been numerous studies over the past two decades documenting the prevalence
of pathology within cadaveric donors. Studies by Wood et al demonstrated the presence of
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numerous pathologies in a small sampling of cadaveric donors aged 76-98 years, with each
cadaver possessing 3-4 coexisting conditions (Wood et al., 2010), a finding consistent with the
known prevalence of comorbidities in the elderly population (Tisminetzky et al., 2016). Later
studies likewise demonstrated significant prevalence of both documented and undocumented
pathologies in cadaveric donors (Geldenhuys et al., 2016; Plummer et al., 2018), with studies by
Plummer et al reporting that 66% of the cadavers examined displayed significant evidence of
pathologies not implicated in reported COD, although this study did not report the specific
prevalence of different disease classes (Plummer et al., 2018).
While many studies have been conducted regarding the presence of pathology in cadaveric
donors, studies evaluating the prevalence of specific forms of CVD have been more limited.
However, one study reported evidence of heart disease in all 50 cadaveric hearts examined, even
though only 6 donors possessed a CVD-related COD (Chun et al., 2007). A South African study
reported the presence of CVD-related lesions in a larger group of cadaveric donors, but overall
prevalence of CVD was not included, nor is it guaranteed that these findings are applicable to
other countries due to the lower prevalence of CVD in South Africa (Heart and Stroke Foundation
South Africa, 2016). Additional studies assessing CVD in cadavers have reported the presence
of numerous disease forms, but these studies have not provided a comprehensive report regarding
the prevalence of documented vs undocumented CVD or how these values compare in male and
female donors (Wood et al., 2010; AlSaggaf et al., 2010).
Therefore, while these studies have demonstrated the prevalence of CVD in the cadaveric
population, there has not been a comprehensive study comparing documented CVD with gross
and histologic findings in male and female donors for the purpose of identifying undiagnosed
cases of heart disease correlated with heritable heart disease risk factors.
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Genomic Studies in Cadaveric Donors
Since many disease conditions have genetic components, the ability to correlate
undiagnosed disease with specific genetic risk factors would be a powerful diagnostic tool and
allow for the utilization of cadaveric tissue for genomic studies in addition to gross and histologic
ones. Past studies have not utilized embalmed cadaveric tissue for genomic studies due to the
difficulty in extracting and purifying genetic material from formalin-fixed tissue. The formalin
fixation process results in significant cross-linking between nucleic acids and proteins, causing
significant degradation during extraction (Okello et al., 2010; Eltoum et al., 2013; Brenner, 2014;
Hoffman et al., 2015; Sidova et al., 2015) and posing a unique challenge for cadaveric tissue-based
genetic research. Unembalmed cadavers have been utilized for genomic studies (Kumar et al.,
2014), but this also carries significant limitations due to the post-mortem degradation of genetic
material in the absence of preservation (Hansen et al., 2014).
Nevertheless, despite the challenges associated with formalin-fixed tissue, several recent
studies have demonstrated that embalmed tissue can in fact be utilized for identification of genetic
risk factors correlated with disease states. A study by Wheeler et al demonstrated short tandem
repeat (STR) amplification from embalmed cadaveric tissue, but noted significant degradation of
DNA in certain samples. Prolonged 4°C storage time, longer post-mortem interval between death
and embalming or between embalming and dissection, prolonged fixation time, and biological
variation were proposed as possible explanations for this degradation. This study established bone
marrow and muscle tissue as the site of highest quality DNA extraction, although yield was low
and STR profiles often incomplete for all 3 cadavers studied (Wheeler et al., 2017).
In an attempt to improve DNA yield from embalmed tissue, Gielda et al proposed a
modified DNA extraction protocol utilizing a high heat extraction step to dissociate protein-DNA
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crosslinks rather than the standard proteinase K digestion (Gielda et al., 2017). This study
demonstrated effective extraction of DNA from embalmed cadaveric tissue and successfully used
this DNA to genotype 4 cadavers and identify isoforms of the APOE gene correlated with
increased risk of—or protection against—Alzheimer’s disease. The polymorphisms observed in
these cadavers were compared with medical records which confirmed the presence of dementia in
two of the cadavers possessing APOE risk factors for Alzheimer’s disease and the lack of any
neurodegenerative disorders in the cadaver possessing the protective APOE isoform.
While Gielda et al (2017) found that embalmed hearts were correlated with the lowest DNA
yield compared with cerebral cortex, cerebellum, and bone, studies by Gerhard et al found large
amounts of high molecular weight DNA in cadaveric heart tissue even with a proteinase K
extraction step. This study demonstrated successful sequencing of cadaveric DNA for the purpose
of identifying single-nucleotide variants (SNVs) associated with disease risk and also successfully
correlated these findings with documented conditions included in medical records (Gerhard et al.,
2016). These studies confirm that cadaveric tissue is a viable source of material for genomic
analysis, laying the foundation for identification of genetic risk factors for heart disease in this
previously under-utilized source of data.

Rationale and Significance
The studies described here demonstrate that heart disease, while a known health concern
in both young and old alike, may be even more prevalent than is supposed, particularly in elderly
and female members of the population. Furthermore, this undiagnosed heart disease may remain
undiagnosed even after death due to the absence of autopsy examination. While studies have
demonstrated the prevalence of many undiagnosed classes of heart disease through autopsy
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(Sington et al., 2002; Roulson et al., 2005; Ravakhah, 2006; Mieno et al., 2016), there is currently
no comprehensive assessment of undiagnosed heart disease in the significant percentage of the
population not receiving an autopsy. This segment of the population can be studied through
assessment of disease burden in cadaveric donors, but despite cadaver-based studies demonstrating
the presence of undiagnosed heart disease in cadaveric donors (Chun et al. 2007), there has not
been a thorough analysis of true heart disease prevalence compared with medical records that
includes both gross and histologic confirmation. Past studies have also neglected to note the
prevalence of undocumented heart disease in male cadaveric donors compared with female donors,
or how this prevalence may vary in different age groups. Furthermore, while past studies have
demonstrated successful extraction of DNA from formalin-fixed cadaveric donors (Gielda et al.,
2017), there is currently no protocol in place for extraction of RNA from embalmed tissue, and
subsequently, no means of establishing the existence of actively transcribed genetic risk factors
which can be correlated with structural and functional changes associated with heart disease.
In order to gain an accurate understanding of true heart disease burden in the population as
a whole, as well as in males and females individually, prevalence of heart disease in members of
the population not receiving an autopsy after death must be established. Furthermore, in order to
reduce the persistence of unknown heart disease risk in the population, genetic risk factors
correlated with these undocumented conditions must be identified. This study seeks to fill these
gaps by analyzing cadaveric donor tissues on a gross, histologic, and transcriptomic level in order
to obtain a comprehensive understanding of the presence and manifestations of undiagnosed heart
disease in the elderly population. Through transcriptome analysis, this study also seeks to provide
a means of identifying unknown genetic risk factors which may exist in the descendants of these
donors.
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Hypothesis
Based on the data outlined here, I hypothesize that many forms of heart disease within the
elderly and female populations remain undiagnosed in the absence of an autopsy and that a more
accurate assessment of heart disease burden can be obtained through gross and histologic
examination of cadaveric donors. Furthermore, I hypothesize that many cases of both diagnosed
and undiagnosed heart disease in non-autopsied individuals may be associated with genetic risk
factors which can be identified through transcriptome analysis of RNA extracted from formalinfixed cadaveric heart tissue.
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CHAPTER 2
Gross and Histologic Examination of Undocumented Heart
Disease in Male and Female Cadaveric Donors

*Portions of this chapter are published under the title Prevalence of Undocumented
Cardiovascular Disease in Male and Female Cadaveric Donors in the International Journal of
Medical and Health Research, December, 2019 (Passburg, C.D., Mitchell, D.M., Miller, P.M.)
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Summary
Current mortality statistics reveal that heart disease is the leading cause of death
worldwide, contributing to 1 out of every 4 deaths and causing disease-related morbidity in
millions more, with an even greater prevalence of heart disease manifesting with increasing age.
Most diagnoses are based on medical history, but autopsy is considered the gold standard in
identifying the precise cause of death and contributing factors. However, in the USA, the current
autopsy rate is only 8%, suggesting that many individuals thought to be unaffected by heart disease
may possess cardiovascular risk factors contributing to their cause of death. Medical record
examination of 22 male and 28 female cadaveric donors with an average age of ~82 years revealed
that 56% possessed at least one documented form of CVD, 30% of which possessed documented
forms of heart disease. In contrast, gross examination revealed mild to severe CVD in 98% of
donors. Examination of heart-specific CVD in these donors likewise revealed a significant
percentage of undocumented heart disease. A higher prevalence of undocumented heart disease
was detected in female donors, suggesting that females are less likely to be diagnosed with heart
disease. Histologic examination of a subset of these donors confirmed the presence of myocardial
alterations consistent with heart disease both in donors possessing diagnosed CVD and those
without documented forms of CVD. These results suggest that many cases of heart disease remain
undetected in the absence of conventional autopsy, indicating that the prevalence of heart
disease may be much higher than what is commonly accepted, particularly in the elderly and
female populations. These findings are significant since undocumented heart disease in the elderly
places them at an elevated but unknown risk of infectious diseases, and likewise places their family
members at potentially unknown risk of developing heart disease due to the strong genetic
components of many forms of heart disease.
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Introduction
Cardiovascular disease (CVD) encompasses a variety of conditions including myocardial
infarction, (MI), stroke, hypertension, heart disease, and others (Mensah et al., 2007; Virani et al.,
2020). According to the American Heart Association (AHA), nearly half of all adults in the US
are affected by some form of CVD (Virani et al., 2020). These conditions can be identified as the
underlying cause of death in approximately 1 out of every 3 cases, amounting to 859,125 deaths
per year in the US and 17.8 million deaths per year globally, making CVD the leading cause of
death both in the US and worldwide (Heron, 2019; Virani et al., 2020). Heart disease specifically
accounts for the majority of these deaths, causing 647,457 deaths annually in the US (Heron,
2019). Beyond COD, however, heart disease is a common cause of morbidity and disease-related
disability in the US, with ~30.3 million adults estimated to possess one or more forms of heart
disease (Centers for Disease Control and Prevention, 2018a). Prevalence of heart disease is
particularly high in the elderly population, with the Center for Disease Control and Prevention
reporting that 80% of all heart disease-related deaths occur in individuals over the age of 65
(2018b). The AHA likewise reports that 89-91% of individuals over the age of 80 possess one or
more forms of CVD (Virani et al., 2020). A significant proportion of these cases are based on a
diagnosis of hypertension, but even with hypertension excluded, these reports revealed that heart
disease, heart failure, and stroke affect ~34% of females and ~43% of males over the age of 80.
These numbers alone are compelling, but research suggests that there may be a population
of individuals possessing undiagnosed heart disease which remains unknown even after death.
Current statistics for heart disease as an underlying cause of death or significant health condition
are based on medical history and diagnosed cases; however, autopsy is considered the gold
standard for determining the exact cause of death through confirmation of pre-mortem diagnoses
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or identification of undiagnosed conditions (Ravakhah, 2006; Goldman, 2018; Hoyert, 2011).
Current autopsy rates have progressively declined over the past several decades, dropping from
one in every five deaths receiving an autopsy in the 1970s to a mere 8% in 2007 (Hoyert, 2011;
Shojania et al., 2008). These numbers are even lower in the elderly population, with less than 1%
of individuals over the age of 85 receiving an autopsy (Hoyert, 2011). Advanced diagnostic tools
allowing for more accurate pre-mortem diagnoses are thought to be the primary cause of this
drastic decline (Ravahkah et al., 2006; Hamza et al., 2017), but current research has demonstrated
that these pre-mortem evaluations may prove insufficient for a precise diagnosis of an individual’s
cause of death (Roberts et al., 2003; Aiello et al., 2016; Euler et al., 2017). While medical imaging
allows for some level of diagnosis and detection, these techniques cannot provide the same depth
and specificity obtained through postmortem gross and histologic examination.
Previous studies have suggested that many risk factors for heart disease go undetected in
the absence of a conventional autopsy, indicating that the prevalence of heart disease as an
underlying COD or significant medical condition may be much higher than what is commonly
accepted. Since only 8% of all deaths receive an autopsy (Hoyert, 2011), there remains 92% of the
population whose stated cause of death may be inaccurate or incomplete.

Many of these

individuals are presumed to be unaffected by heart disease, but in the absence of an autopsy, this
can neither be confirmed nor denied. Therefore, these individuals may possess unknown heart
disease risk factors contributing to their cause of death which are never revealed due to the absence
of a conventional autopsy.
Some have argued, however, that the prevalence of discrepancies in death certificates is
due to a selection bias, where these cases are prone to discrepancy because uncertainty regarding
COD was the very reason they were referred for autopsy (Shojania et al., 2008). While other
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studies have refuted this proposition (Shojania et al., 2003), there remains a level of uncertainty
since many individuals die without receiving an autopsy and there is no way of knowing whether
they did or did not possess undiagnosed heart disease.
Cadaveric donors provide a novel and accessible means of studying disease burden in the
portion of the population not receiving an autopsy following death. None of these individuals
received an autopsy prior to donation and many studies utilizing cadaveric donors have reported a
wide range of both documented and undocumented disease (Chun et al., 2007; AlSaggaf et al.,
2010; Wood et al., 2010; Geldenhuys et al., 2016; Rae et al., 2017; Plummer et al., 2018).
However, most of these studies have performed analyses from an educational standpoint; as such,
they have focused on undocumented disease as a means of incorporating pathology into gross
anatomy labs and have not approached these findings as health disparities which could have
significant ramifications for family members, as well as the population as a whole.
Our study seeks to fill this gap by providing a thorough assessment of heart disease in a
population of primarily elderly cadaveric donors for the purpose of identifying undocumented
heart disease. This will allow for a more accurate and comprehensive understanding of heart
disease prevalence in the elderly male and female populations.

Materials and Methods
Pathology Report Analysis
This study examined hearts from 22 male and 28 female adult human cadavers routinely
utilized in gross anatomy dissection courses in the Department of Biology and Chemistry at
Liberty University in Lynchburg, VA, USA. Out of the 50 donors, 38 were obtained from Virginia
State Anatomical Program (Richmond, VA), 7 were obtained from MedCure (Orlando, FL), and

37

5 were obtained from Marshall University (Huntington, WV). Documented CVD was determined
by routine examination of pathology reports provided by donor facilities. These documents
provide the underlying COD as well as additional health information provided by family members
and general practitioners. In a few cases, medical records did not include a heart disease diagnosis,
but dissection revealed a pacemaker or coronary artery bypass graft; these individuals were
included in the study group possessing documented heart disease.

Gross Dissection and Examination
Cadaveric hearts were removed from the mediastinum by removing the pericardial sac and
cutting through the ascending aorta, pulmonary trunk, superior vena cava, inferior vena cava, and
pulmonary veins (Detton, 2016). A frontal cut was made through the entire heart to reveal all four
chambers. Gross morphology was observed to reveal any abnormalities. The left ventricular wall
thickness was measured 1.5cm below the mitral valve hinge line, as described in previous studies
(Ho, 2009). Hearts were classified as normal if they possessed a left ventricular thickness of 1215mm, with values greater than 15mm classified as hypertrophic and values less than 12mm
classified as dilated (Rae et al., 2017). Measurements of right ventricular wall thickness were
taken in the upper one-third of the distance between the tricuspid valve annulus and the right
ventricular apex, as described in previous studies (Ho et al., 2006). Hearts with a right ventricular
thickness of 3-5mm were classified as normal, with values greater than 5mm classified as
hypertrophic and values less than 3mm classified as dilated, excluding trabeculations (Rae et al.,
2017). These classification standards were utilized for all heart sample measurements; however,
it was noted that for 4 samples, the standard measurements for right-side ventricular thickness
designated them as hypertrophic or normal, while gross observation displayed severe dilation,
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suggesting that revision of right-sided ventricular classification methods may be advisable for
more accurate identification.

Statistical Analysis
Statistical significance of documented vs observed prevalence was calculated by chi-square
analysis.

Fisher’s exact tests were utilized for determining statistical significance of

undocumented disease prevalence between gender and age groups.

Histologic Examination
Histologic examination of heart tissue was performed using cryostat sectioning and
standard H&E and trichrome staining. Samples were taken from the left ventricle myocardium
and cut into ~7.5mm2 sections. Tissue samples were rinsed in phosphate buffered saline (PBS) to
remove excess formalin and transferred to 50mL conicals containing 15-20mL of Pelco Cryoembedding compound (Ted Pella Inc., Redding, CA) for infiltration. Samples were left in
embedding media overnight to facilitate complete infiltration of the samples prior to freezing.
Following infiltration, samples were transferred to cryostat molds containing fresh embedding
media and placed in a dry ice/100% ethanol bath until fully frozen. Frozen molds were stored at
-20°C prior to sectioning. Samples were sectioned at -25°C using a Leica CM1860 UV Cryostat
at a thickness of 7µm and stored on polarized microscope slides. Prior to standard Trichrome
staining, slides were exposed to an overnight infiltration in Bouin’s solution, followed by thorough
rinsing in PBS. Samples stained with H&E were also rinsed in PBS prior to staining. Slides were
imaged with a Leica ICC50 microscope and Leica LAS EZ Microsystems imaging software.
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Results
Pathology reports reveal documented CVD prevalence in over half of donors
Certain studies have reported that cadaveric donor populations display a bias towards
individuals possessing CVD (Collins 2018). Our studies likewise demonstrated an abundance of
documented CVD, although this is consistent with the advanced age of our cadavers (North 2012)
and may not be due to any sort of cadaveric bias. Out of 50 cadaveric donors, CVD was the most
frequently reported COD, with 36% possessing CVD as their documented COD, compared to 24%
possessing cancer, the second highest COD (Figure 2.1A). When secondary medical conditions
were taken into account, documented prevalence of CVD rose to 56% (Figure 2.1B), likewise
making it the most frequently reported medical condition and confirming the known abundance of
CVD reported in the elderly population (Virani et al., 2020). Further analysis of death certificates
also revealed that of the donors possessing CVD as a COD or secondary medical condition, 15
possessed documented heart disease, while the remaining donors possessed various forms of
peripheral vascular disease (Table 2.1). It was also observed that out of those possessing
documented CVD, 19 possessed only one documented form of CVD, but 9 donors possessed two
or more documented forms of CVD.

Cardiovascular disease remains unidentified in the absence of autopsy in cadaveric donors
Gross examination of all 50 donors revealed the presence of features consistent with mild
to severe CVD in 49 individuals, confirming the presence of CVD in the 28 diagnosed individuals
and revealing the presence of undocumented CVD in 21 of the remaining donors (Table
2.2). Additionally, in those cases where one form of CVD was documented, gross examination in
many cases revealed additional undocumented forms of CVD. Therefore, whereas the prevalence
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Figure 2.1 Frequency of medical conditions reported in cadaveric donors records.
(A) Frequency of conditions reported as COD in medical records for cadaveric donors revealing
the significant prevalence of CVD as COD, n=50. It was noted that for 6 of the cadavers, two
distinct conditions were listed as cause of death. These cases are reported twice in this chart in
order to reflect the full extent of conditions reported as COD in medical records.
(B) Frequency of conditions reported as COD or secondary medical condition in medical
records for cadaveric donors reflecting the extensive prevalence of CVD in over half of the
donors examined, n=50.

41

CVD Class

Number of Donors Possessing
Specific Class of Documented
CVD

Heart Disease

15

Hypertension

9

Cerebrovascular Disease

9

Peripheral Vascular Disease

3

Thromboembolism

3

Disseminated Intravascular
Coagulation

1

Table 2.1 Documented cardiovascular conditions reported in cadaveric donor medical
records as cause of death or secondary medical condition.
Analysis of donor medical records for the 28 donors possessing documented CVD revealed
heart disease as the most common class represented, with 15 out of the 28 CVD-affected
donors specifically possessing a diagnosis of heart disease. Hypertension and cerebrovascular
disease were the most frequently documented forms of vascular disease, although other less
common vascular conditions were also reported. Certain cadavers possessed multiple forms
of documented CVD, and these coexisting conditions are individually reported here to reflect
the full extent of CVD diagnoses represented in these donors.
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of CVD in these donors according to death certificate information was only 56%, gross
examination revealed that this value may be as high as 98%, supporting the concern that many
forms of CVD remain undiagnosed in the absence of autopsy examination (Figure 2.2).

Undocumented heart disease is found in the majority of cadaveric donors
Further evaluation of donor health records revealed that of the donors possessing
documented CVD, 15 had been diagnosed specifically with heart disease, either as a COD or as
an underlying health condition. In contrast, gross examination revealed features consistent with
various forms of heart disease such as hypertrophy or dilation of the ventricular walls, atrial
dilation, valvular calcification, and coronary artery calcification in an additional 25 donors (Table
2.2). Measurements consistent with hypertrophy or dilation of the heart and a variety of additional
heart disease features were observed in 22 of these donors; the remaining 3 donors possessed
normal ventricular measurements but displayed other forms of heart disease. This suggests a 98%
prevalence of heart disease in cadaveric donors as opposed to the 30% possessing heart disease
according to medical records (Figure 2.2).

Significant undocumented CVD is observed in both male and female donors
Assessment of CVD in male donors compared with female donors revealed that a higher
percentage of female donors possessed undocumented CVD compared with male donors, but this
difference was not found to be statistically significant (Figure 2.3A, Table 2.3). 64% of male
donors possessed CVD as a primary or secondary health condition according to documented health
records, but only 46% of female donors possessed documented CVD.

However, autopsy

examination revealed a similar prevalence of features consistent with CVD in both male and
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Figure 2.2 Frequency of CVD and heart disease cadaveric donors records compared
with observed prevalence by gross examination.
Gross examination revealed significantly increased prevalence of CVD in cadaveric donors
compared with prevalence reported in donor medical records (p = <0.00001). Examination of
heart-specific CVD likewise revealed significant undocumented prevalence of heart disease in
cadaveric donors compared with reported heart disease in medical records (p = <0.00001). All
cadaveric donors possessing CVD also possessed gross features consistent with heart disease,
although peripheral forms of CVD were also noted, n=50.
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Pathology

Documented
Records

Gross
Examination

Donors Possessing CVD

28

49

Donors Possessing Heart
Disease

15

49

Table 2.2 Number of donors possessing CVD and heart disease according to documented
records and gross examination.
Gross examination of cadaveric donors revealed that while only 28 donors possessed
documented forms of CVD, a total of 49 donors possessed features consistent with various
forms of CVD, n=50. Likewise, comparison of documented heart disease prevalence compared
with gross findings revealed that while only 15 donors possessed documented heart disease, a
total of 49 donors displayed features consistent with mild to severe forms of heart disease, n=50.
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female donors, with 100% of male donors and 96% of female donors possessing features consistent
with mild to severe forms of CVD. Therefore, undocumented CVD was observed in 36% of male
donors and 50% of female donors.
Examination of heart-specific CVD according to medical records compared with gross
measurements revealed a statistically significant difference in frequency of undiagnosed heart
disease between male and female donors (Figure 2.3B, Table 2.3). Of the 22 male cadavers
assessed, 50% possessed documented heart disease, compared to only 11% of the 28 female
cadavers examined. However, our examination of gross cardiac pathology in male and female
donors revealed features consistent with mild to severe forms of heart disease in an additional 50%
of male donors and an additional 86% of female donors. Therefore, whereas only 50% of male
cadavers and 11% of female cadavers possessed documented forms of heart disease, gross
examination revealed features consistent with heart disease in 100% of male cadavers and 96% of
female cadavers.

Younger female donors are more likely to possess undocumented heart disease than males
Comparison of CVD incidence in cadaveric donors by age group also revealed changes in
prevalence based on age for CVD in both males and females, and for heart disease in females, but
these differences were not considered statistically significant (Figure 2.4, Table 2.4). These
findings revealed that prevalence of CVD according to documented records was lower in females
under the age of 85 (31%) than in females over the age of 85 years (60%). Prevalence of CVD in
males showed a less drastic change, increasing from 57% in men under 85 years to 75% in men
over 85. Prevalence of heart disease in females also increased with age: only 8% of women under
the age of 85 were reported as possessing a documented form of heart disease, whereas 20% of
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A

B
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Figure 2.3 Prevalence of CVD and heart disease in male and female donors according to
documented records compared with results based on gross examination.
(A) Medical records revealed that 64% of male donors possessed documented CVD, contrasted
to the 46% of female donors possessing documented CVD. Gross examination of donors
lacking documented CVD revealed that the remaining 36% of male donors possessed evidence
of undocumented CVD and an additional 50% of female donors possessed evidence of
undocumented CVD.
Chi-square analysis revealed significant differences between
documented and observed prevalence for both males (p=0.0004) and females (p=<0.00001),
but Fisher’s exact test revealed no statistically significant difference between likelihood of
undocumented disease in males compared with females (p=0.388). Male, n=22; female, n=28.
(B) Medical record analysis for documented heart disease revealed that half of male donors
possessed documented heart disease (n=22), while only 11% of female donors displayed
documented forms of heart disease (n=28). Gross examination, however, revealed that the
remaining 50% of male donors also possessed evidence of heart disease, and female donors
displayed significant evidence of undocumented heart disease, with 86% of female donors
displaying features consistent with heart disease without any corresponding documentation of
cardiac conditions. Chi-square analysis revealed significant differences between documented
and observed prevalence for both males (p=<0.00001) and females (p=<0.00001), and Fisher’s
exact test demonstrated that females were significantly more likely to possess undocumented
heart disease compared with males (p=0.0041). Male, n=22; female, n=28.
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Documented Disease

Undocumented
Disease

Total

Male CVD
(n=22)

14 (64%)

8 (36%)

22 (100%)

Female CVD
(n=28)

13 (46%)

14 (50%)

27 (96%)

Male Heart
Disease (n=22)

11 (50%)

11 (50%)

22 (100%)

Female Heart
Disease (n=28)

3 (11%)

24 (86%)

27 (96%)

Table 2.3 Number of male and female donors possessing CVD and heart disease according
to documented records and gross examination.
Comparison of documented CVD and heart disease prevalence with observed prevalence based
on gross examination revealed that both males and females possessed significant
undocumented CVD and heart disease. These results also revealed that while there was no
statistically significant difference in likelihood of undocumented CVD in males compared with
females, Fisher’s exact test revealed that females were more likely to possess undocumented
heart disease than male donors (p=0.0041).
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Figure 2.4 Documented vs total prevalence of CVD and heart disease in male and female
cadaveric donors by age group.
(A) Age-specific analysis of CVD in male and female cadaveric donors revealed that
percentages of diagnosed CVD cases increased in both males and females over the age of 85
(Female, n=15; male, n=8) compared to individuals under the age of 85 (Female, n=13; male,
n=14), but these differences were not found to be statistically significant based on Fisher’s
exact tests (male, p=0.6494; female, p=0.1283). Gross examination revealed that total
confirmed prevalence of CVD was comparable between age groups, demonstrating significant
prevalence of undocumented CVD in older female donors (p=0.0084) and in younger male and
female donors (male, p= 0.0012; female, p=<0.00001) based on chi-square analysis. Presence
of undocumented CVD in older male donors was not found to be statistically significant
(p=0.1025). A higher percentage of female donors in both age groups possessed undocumented
CVD compared with undocumented CVD in males, but these were not found to be statistically
significant differences based on Fisher’s exact tests (<85 years, p=0.2; ≥85 years, p=1).
(B) Age-specific analysis of heart disease in male and female cadaveric donors revealed that
diagnosed heart disease was more prevalent in females over the age of 85 than in females under
the age of 85, although this difference was not found to be statistically significant by Fisher’s
exact test (p=0.05956) (<85 years, n=13; >85 years, n=15). Documented heart disease was
equally prevalent in males over the age of 85 as in males under the age of 85 (p=1) (<85 years,
n=14; >85 years, n=8). However, gross examination revealed that the total prevalence of gross
features suggestive of heart disease was comparable between age groups and demonstrated
significant undocumented heart disease in both older (male, p=0.0047; female, p=<0.00001)
and younger donors (male, p= 0.0002; female, p=<0.00001) by chi-square analysis. Gross
examination also revealed that prevalence of features indicative of heart disease was
comparable between males and females in both age groups, but that females were significantly
more likely to possess undocumented heart disease than male donors in individuals under the
age of 85 (p=0.0329). While the percentage of females possessing undocumented heart disease
in individuals over 85 was higher than the percentage of males in the same age bracket, this
relationship was not found to be statistically significant based on Fisher’s exact test (p=0.3426).
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Documented

Undocumented

Total

<85 years
n=13

F/CVD

4

9

13 (100%)

F/Heart Disease

1

12

13 (100%)

<85 years
n=14

M/CVD

8

6

14 (100%)

M/Heart
Disease
F/CVD

7

7

14 (100%)

9

5

14 (93%)

F/Heart Disease

3

11

14 (93%)

M/CVD

6

2

8 (100%)

M/Heart
Disease

4

4

8 (100%)

≥85 years
n=15
≥85 years
n=8

Table 2.4 Male and female cadaveric donors possessing documented/undocumented
CVD and heart disease by age group.
Analysis of age-specific prevalence of CVD and heart disease in male and female donors
revealed that females under the age of 85 were significantly more likely to possess
undocumented heart disease than males in the same age group (p=0.0329). While higher
percentages of females were found to possess undocumented heart disease in higher age
brackets than males of the same age, these differences were not found to be statistically
significant. No statistically significant difference was observed between total confirmed
prevalence of heart disease and CVD between males and females or between older and younger
donors based on gross examination, with all male donors possessing evidence of CVD and heart
disease, and the vast majority of female donors possessing similar features.
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women over 85 possessed diagnosed heart disease. In male donors, however, heart disease
prevalence did not change, remaining at 50% for both individuals under 85 and individuals over
85 years of age. Subsequently, there were lower percentages of undocumented CVD in both male
and female donors over 85, and lower percentages of undocumented heart disease in females over
the age of 85. However, while many donors displayed undocumented CVD and heart disease in
both age groups, the only statistically significant difference was observed between undocumented
heart disease in male and female donors under the age of 85, with females in this age range being
significantly more likely to possess undocumented heart disease than males of the same age.

Histologic examination confirms gross features of heart disease
In order to determine whether gross measurements correlated with the presence or absence
of histopathologic features within the myocardium, tissue samples were isolated from the free
wall of the left ventricle in 7 cadaveric hearts and prepared for histologic analysis. Normal left
ventricular measurements were observed in 2 of the samples and these hearts were classified as
controls (Figure 2.5A and D). Documented forms of CVD and measurements indicative of
myocardial pathology were observed in 3 samples (Figure 2.6A, E, and I), and the remaining 2
samples possessed gross measurements indicative of heart disease, but without any documented
forms of CVD (Figure 2.7A and D).
Histology of the two control heart samples established one as a true control sample but the
other as a false negative. Examination of control donor 1 displayed histology consistent with
healthy heart tissue, possessing standard collagen distribution throughout the myocardium and
normal cardiomyocyte color and appearance (Figure 2.5B and C). The presence of lipofuscin
accumulation around the nucleus was also observed, which has been associated with
cardiomyopathy (Radu et al., 2012); however, studies in the elderly population have indicated that
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lipofuscin accumulation is directly correlated with aging even in the absence of cardiac pathology
(Kakimoto et al., 2019), making it likely that the lipofuscin observed in these cadavers is due to
their advanced age rather than being a conclusive indicator of heart disease. Therefore, while in
the cases of certain donors, lipofuscin may be pathologically relevant, it was not considered a
conclusive indication of disease in our study due to the predominantly elderly population
represented. While the heart of control donor 1 was confirmed to be healthy by histologic
examination, histology of control donor 2 revealed extensive fibrosis within the myocardium
(Figure 2.5E and F), a feature indicative of cardiac stress which causes impaired function of the
heart and is associated with myocardial pathology (Wolf et al., 2005; Camelliti et al., 2005;
Espeland et al., 2018). Therefore, the second control heart was classified as a false negative based
on histologic examination and was established as an additional example of undiagnosed CVD.
The three hearts possessing documented CVD all displayed ventricular features consistent
with heart disease, although only 1 out of the 3 donors possessed a documented form of heart
disease which would be expected to produce myocardial alterations consistent with the
pathological features observed. However, the remaining 2 diseased samples possessed non-cardiac
forms of CVD which could still be correlated with the abnormal ventricular measurements based
on the close relationship between peripheral vascular disease and heart disease (Chen et al., 2017).
Diagnosed CVD donor 1, possessing documented heart disease, displayed evidence of both
diffuse and perivascular fibrosis (Figure 2.6B-D), a finding which was consistent with the
diagnosis of congestive heart failure (Wolf et al., 2005; Radu et al., 2012). Diagnosed CVD donors
2 and 3 did not possess documented forms of heart disease, but both had died from cerebrovascular
disease and possessed ventricular measurements indicative of heart disease. Diagnosed CVD
donor 3 also displayed evidence of an undocumented myocardial infarction in the base of the left
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Figure 2.5 Comparison of cadaveric donor hearts possessing normal left ventricular
measurements and lacking documented forms of CVD.
(A) Gross examination of control donor 1 revealed normal ventricular measurements in the left
ventricle, but minor hypertrophy of the right ventricle. (B-C) Histologic examination of the
left ventricle in control donor 1 revealed standard perivascular collagen arrangements with
minor interstitial fibrosis. Normal cardiomyocyte appearance with coloration and branching
patterns expected in healthy myocardial tissue was also observed; Trichrome. (D) Gross
examination of control donor 2 revealed normal ventricular measurements, although minor
enlargement of the right ventricle was observed. (E-F) Histologic examination of control donor
2 revealed extensive perivascular and interstitial fibrosis within the myocardium—indicative
of myocardial pathology—along with purple appearance to the cardiomyocytes, a feature which
may be indicative of myocardial ischemia (Ouyang et al., 2010); Trichrome.
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ventricle (Figure 2.6I). Histologic examination for both donors revealed significant myocardial
alterations consistent with gross observations. Significant interstitial fibrosis was observed in the
myocardium of diagnosed CVD donor 2, correlating with the hypertrophic measurements observed
in both ventricular walls (Figure 2.6F-H). Diagnosed CVD donor 3 likewise possessed connective
tissue infiltrate, but in this case, the collagen was more diffusely spread between the
cardiomyocytes, and the cells displayed an elongated, wavy appearance. This indicated stretching
of the myocardium which was consistent with the dilated ventricular measurements observed
through gross analysis (Radu et al., 2012) (Figure 2.6K-L). Diagnosed CVD donor 3 also
possessed cardiac lipomatosis within the myocardium (Figure 2.6J), a histologic feature indicative
of various forms of heart disease (Patra et al., 2013; Anumonwo and Herron, 2018). Cardiac
lipomatosis has been associated with cardiac arrhythmias, cardiomyopathies, and the heart’s
response to healing after a myocardial infarction, but has also been considered a part of ageassociated degeneration of the heart (Biernacka and Frangogiannis, 2011; Zamarrón-de Lucas et
al., 2016). While cardiac lipomatosis has been associated with aging, the fatty infiltration observed
here is likely correlated with a previous myocardial infarction based on the evidence of necrotic
tissue at the base of the left ventricle (Matsuo et al., 2013).
The two donors possessing ventricular measurements consistent with heart disease but
lacking documented CVD also displayed histologic features consistent with gross examination.
Undiagnosed CVD donor 1 displayed severe left ventricular hypertrophy and dramatically reduced
chamber size (Figure 2.7A), and histologic examination revealed extensive perivascular fibrosis
throughout the myocardium (Figure 2.7B-C).

Undiagnosed CVD donor 2 displayed left

ventricular dilation (Figure 2.7D) and histologic examination revealed purple discoloration of the
cardiomyocytes after trichrome staining, a feature indicative of myocardial ischemia (Ouyang et
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Figure 2.6 Comparison of cadaveric donor hearts possessing pathologic ventricular
measurements and documented CVD.
(A) Gross examination of diagnosed CVD donor 1 revealed normal ventricular measurements
but with evidence of a myocardial infarction in the left ventricle. (B-D) Histologic examination
of diagnosed CVD donor 1 revealed extensive perivascular fibrosis and collagen infiltration
throughout the myocardium; Trichrome. (E) Gross examination of diagnosed CVD donor 2
revealed bilateral ventricular hypertrophy. (F-H) Histologic examination of diagnosed CVD
donor 2 revealed extensive interstitial fibrosis throughout the myocardium, Trichrome. (I)
Gross examination of diagnosed CVD donor 3 revealed right ventricular hypertrophy, left
ventricular dilation and evidence of a myocardial infarction at the base of the left ventricle. (J)
Histologic examination of the left ventricular myocardium revealed cardiac lipomatosis, a
feature indicative of post-myocardial infarction healing (Matsuo et al., 2013); Trichrome. (KL) Histologic examination also revealed wavy, elongated appearance to the cardiomyocytes, a
feature consistent with gross observation of ventricular dilation; Trichrome.
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al., 2010) (Figure 2.7E-F). This donor also possessed increased vascularity within the tissue, as
evidenced by the abundance of red blood cells and capillaries present in the myocardial
architecture. Myocardial angiogenesis is uncommon in the adult heart except in pathologic or
hypoxic conditions, and is a known response to ischemia (Hudlicka, 1982; Toyota et al., 2004;
Robich et al., 2011). While angiogenesis can occur naturally in response to exercise (Bellafiore et
al., 2019), the combination of pathologic features observed in this donor’s heart make it more
likely that the observed angiogenesis was correlated with myocardial ischemia. Complete details
regarding donor medical information, gross observations, and histologic features are provided in
Table 2.5.

Discussion
Inaccuracies in COD reported on death certificates in the absence of autopsy
Many studies have demonstrated that the cause of death (COD) included on an individual’s
death certificate is often inaccurate or significantly incomplete, lacking pertinent medical
information which likely played a significant role in the individual’s cause of death (Aiello, 2016;
Friberg et al., 2019). Although there have been differing reports regarding whether CVD is overreported or under-reported in the absence of autopsy examination (Nashelsky et al., 2003; Huh et
al., 2013), additional studies have demonstrated numerous inaccuracies in reporting CVD as COD
(Ravakhah, 2006; Mieno et al., 2016). These studies suggest that CVD is frequently misdiagnosed
in the absence of an autopsy and may be over- or under-reported, depending on the specific type
of CVD represented.
A study in 2006 compared death certificates with autopsy reports in 223 cases and revealed
that certain forms of cardiovascular disease such as myocardial infarction, cardiomyopathy, and
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Figure 2.7 Comparison of cadaveric donor hearts possessing pathologic ventricular
measurements in the absence of documented CVD.
(A) Gross examination of undiagnosed CVD donor 1 revealed right ventricular dilation and
severe left ventricular hypertrophy, possibly related in part to observed mitral valve
calcification. (B-C) Histologic examination of undiagnosed CVD donor 1 revealed extensive
interstitial fibrosis within the myocardium; Trichrome. (D) Gross examination of undiagnosed
CVD donor 2 revealed normal right ventricular measurements and left ventricular dilation. (EF) Histologic examination revealed extensive angiogenesis within the myocardium and purple
discoloration to the cardiomyocytes; Trichrome.
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Table 2.5 Demographic, gross, and histologic information for each of 7 cadavers selected
for histologic analysis.
Presence or absence of pathology in cadaveric donor hearts was confirmed by histologic
analysis in 7 cadaveric donors. Gross ventricular measurements and observations are
documented, along with histopathologic features observed in the left ventricular myocardium.
Analysis of two control samples revealed normal myocardial tissue in control donor 1, but
control donor 2 displayed histologic evidence of heart disease pathology despite normal left
ventricular measurements. All donors possessing diagnosed CVD displayed histologic
evidence of cardiac pathology, although only one of these donors specifically possessed a
documented heart disease diagnosis. Both donors displaying gross evidence of heart disease in
the absence of documented CVD diagnoses also displayed histologic evidence confirming gross
observation and indicating the presence of undiagnosed heart disease in these donors.
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aortic aneurysms were frequently underreported and misdiagnosed (Ravakhah, 2006), whereas
other forms of CVD such as cardiac arrhythmia and cardiopulmonary arrest were over-reported.
More recently, Mieno et al analyzed 562 autopsy reports and discovered that 115 disagreed
completely with the stated COD. This study further demonstrated that within patients confirmed
through autopsy to possess heart disease as their cause of death, only 60% had been correctly
identified as having died of heart disease according to death certificates, while the remaining
40% had been assigned an inaccurate or incomplete diagnosis (2016). These results suggest that
certain forms of CVD—and many specific forms of heart disease—are frequently under-reported
as COD, solidifying the necessity of autopsy examination for an accurate assessment of heart
disease-related death rates in the population.

Undiagnosed cardiovascular disease in the absence of autopsy
However, these findings specifically related to the primary COD included on death
certificates. In many cases, however, a more serious concern is that of overlooking undiagnosed
medical conditions that were not the primary cause of death. Since the events leading to death are
often multifactorial in nature (Torabi et al., 2009), it is likely that many significant underlying
conditions could be overlooked if an autopsy is not required in situations where a pre-existing
medical condition is already known and assumed to be the clear cause of death (Alpérovitch et al,
2009).

While these conditions were not the initial cause of death, their presence remains

significant, both in regards to their potential role as a contributing factor in cause of death, as well
as in relation to potential genetic predisposition of family members. Studies have confirmed that
many forms of disease are only detected upon autopsy examination, with myocardial infarction
being the most frequently undiagnosed feature (Friberg et al., 2019). In the elderly population in
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particular, underlying CVD is much more prevalent than is suggested by medical records, with
one study reporting evidence of CVD upon autopsy in 39 out of 40 individuals over the age of 90,
but with many of these individuals having no record of pre-mortem CVD diagnoses (Waller and
Roberts, 1983). These findings suggest that postmortem diagnoses assigned in the absence of an
autopsy may be unreliable or incomplete, and that CVD may affect a larger percentage of the
population than is currently supposed.

Undiagnosed CVD in cadaveric donors
However, quite apparently, these studies were all performed in patients receiving an
autopsy, making it difficult to ascertain whether the findings are transferrable to the remaining
portion of the population or whether a selection bias does indeed exist in those receiving an autopsy
(Shojania et al., 2008). Studies by Waller et al and Shirani et al confirmed the extensive prevalence
of undocumented CVD in elderly individuals receiving an autopsy from the late 1960s to early
1990s (Waller et al., 1983; Shirani et al., 1994), but these studies were performed when autopsy
rates were higher (Hoyert, 2011) and overall CVD death rates were also reported to be higher
(Virani et al., 2020). Therefore, it is difficult to ascertain whether these findings are consistent
with what would be observed in the current elderly population.
Studies in the cadaveric donor population would be expected to provide a more accurate
depiction of disease burden in the absence of autopsy examination since none of these donors
would have received an autopsy prior to death. Studies by Wood et al have demonstrated extensive
pathologic findings in elderly cadavers, reporting that each cadaver possessed 3-4 comorbidities
and there was extensive evidence of CVD, including several forms of heart disease (Wood et al.,
2010). However, these findings were not correlated with documented health conditions and
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specific information regarding demographic characteristics and the numbers of cadavers
possessing each disease class were not provided. This study also lacked histologic confirmations.
Studies by Geldenhuys et al also demonstrated the presence of multiple CVD classes within
a larger population of cadaveric donors and confirmed these findings histologically; however, the
average age of these cadavers was 49.2 years, making it less applicable to the elderly population
as a whole (2016). In addition, this study was conducted at a university in South Africa where
CVD prevalence—while still being the 2nd leading COD—is significantly lower than that observed
in the US (Heart and Stroke Foundation South Africa, 2016; Verani et al., 2020), making these
findings difficult to apply to populations in other countries.
Some of the most recent cadaveric studies reported extensive evidence of pathologies
beyond those associated with stated COD in elderly cadavers (Plummer et al., 2018). These
findings were confirmed by histology, but information regarding the specific disease classes
represented was not included, nor was there any information regarding pathologies present in male
vs female cadavers and how these correlated with documented conditions.
Earlier studies in cadaveric donors which specifically analyzed embalmed hearts likewise
revealed extensive pathologic features, with Chun et al reporting that all 50 donor hearts examined
in their study possessed at least one pathology, although CVD as a COD was only documented in
6 donors according to medical records (Chun et al., 2007). However, presence of documented
CVD as a secondary clinical feature was not reported, and no specific comparison of disease
presence in documented vs undocumented cases was provided. Furthermore, disease prevalence
in male and female donors was not reported and no age range for the donors was provided. This
study also did not incorporate histologic analysis and classified LVH as >12mm rather than the
current standard parameter of >15mm (Gersh et al., 2011; Elliot et al., 2014), making it possible
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that LVH was over-reported in this study. Later heart-specific studies likewise analyzed a total of
50 cadaveric hearts and demonstrated the presence of numerous pathologies, but these findings
were approached as a teaching opportunity for medical students rather than a report of specific
disease conditions, and therefore no specific demographic or statistical information was included
(AlSaggaf et al., 2010).
Our findings likewise revealed a high prevalence of undocumented heart-specific forms of
CVD, suggesting that heart disease is frequently under-diagnosed and making it likely that many
individuals possess undiagnosed heart disease. Our studies revealed undocumented CVD in
individuals between the ages of 40-97 in males (average of 80±12 years) and 59-109 in females
(average of 84±11 years), confirming the results of previous studies (Waller et al., 1983) in a
wider—and more current—sector of the elderly population.

Underdiagnosis of CVD in females
Our findings also revealed that while CVD is more commonly diagnosed in male patients
before death, CVD may be equally prevalent in female patients but underdiagnosed. It is welldocumented that certain forms of heart disease are more common in males than in females (Seki
et al., 2016), and medical records from the donors examined here support the higher rate of heart
disease diagnosis in the male population. However, some studies have reported that certain types
of heart disease are underdiagnosed in females due to the fact that certain parameters for heart
disease are based on male standards which do not perfectly translate to female anatomy (Klodas
et al., 1996). This is not unexpected considering that factors such as height, weight, and gender
can influence regular heart parameters (Pfaffenberger et al., 2013). However, studies in elderly
individuals specifically have demonstrated that frequencies of vascular disease and certain types
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of heart disease are not significantly different between genders and in some cases are more
prevalent in females (Seki et al., 2016). An equal prevalence between males and females was
demonstrated in our studies, but was not supported by medical record examination, implying that
many of these cardiovascular conditions were underreported in the female population.
The concept of gender-based health disparities in the female population has been a topic of
much discussion over the past two and a half decades, since women are often underrepresented in
clinical trials, resulting in male-based standards for diagnosis and treatment which may not apply
to disease progression and manifestation in females (Heiat et al., 2002; Pfaffenberger 2013;
Mazure et al., 2015). Females have been observed to present with different symptoms and disease
characteristics than males (Lenzen et al., 2008; Chokshi et al., 2010; Hemal et al., 2016) which
may not be readily detected by current diagnostic strategies or recognized as symptoms of a future
cardiac event by the patient or by general practitioners (Chokshi et al., 2010; McSweeney et al.,
2000; Chin et al., 2016).
These factors, coupled with the lower autopsy rate in females (Friberg et al., 2019), make
it possible that many cases of CVD could remain undiagnosed in the female population, a premise
supported by the significant prevalence of undocumented heart disease observed in this study.
This carries significant implications for the elderly female population since it suggests that many
individuals living currently may possess CVD which is not recognized or diagnosed. Certain
studies have shown that the atypical symptoms of an impending myocardial infarction may be
present for up to 2 years before the event occurs (McSweeney et al., 2000), making prevention
feasible if true burden of heart disease prevalence can be recognized in the elderly female
population.
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Histopathology of CVD
However, it is important to note that ventricular measurements alone are insufficient for
identification of heart disease. While echocardiographic measurement of ventricular thickness and
heart anatomy is a common method for pre-mortem diagnosis of heart disease, physiologic testing
such as electrocardiographic evaluation is often utilized to confirm gross findings (Japp et al.,
2016; Marian and Braunwald, 2017). Our study likewise revealed that certain cases of documented
CVD which would be expected to produce myocardial alterations were associated with seemingly
normal ventricular measurements. This implies that if individuals possessing confirmed heart
disease could display normal ventricular thickness, it is possible that individuals lacking
documented CVD might also possess undiagnosed heart disease, despite normal ventricular
measurements.
Since ventricular measurements may disguise underlying forms of heart disease or suggest
heart disease where it may not be present, histologic examination of the myocardium is necessary
for accurate post-mortem identification of heart disease. While there has been debate regarding
whether formalin-fixed tissue can be used for reliable histologic examination, recent studies have
demonstrated that formalin-fixed cadaveric tissue can be used for reliable histologic examination
(Nicholson et al., 2005; Wood et al., 2015) and that cadaveric hearts in particular serve as a reliable
source of histologic data (Rae et al., 2018).
Most of the hearts examined histologically in this study revealed extensive fibrosis, a
feature strongly correlated with cardiac stress and pathology (Wolf et al., 2005; Camelliti et al.,
2005; Espeland et al., 2018). It is important to note that a certain level of interstitial fibrosis has
been found to be typical of elderly individuals (Espeland et al., 2018; Kakimoto et al., 2019), and
studies have revealed that collagen fibers surrounding cardiomyocytes tend to increase in number
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and thickness as individuals age (Debessa et al., 2001). However, these studies also revealed that
collagen fiber arrangement does not significantly change over time, making any variations in
perivascular and interstitial arrangement of collagen in our samples pathologically significant.
Furthermore, it is important to note that while fibrosis might be considered “normal” in the elderly,
its presence is nevertheless pathologic. Fibrosis impairs proper function of the myocardium by
causing the ventricles to become stiff and hardened, reducing their capacity to accommodate the
demands of the body and often leading to both diastolic and systolic dysfunction (Espeland et al.,
2018). In addition, the presence of increased fibrotic tissue has also been found to impair
conduction of electrical signals throughout the heart (Biernacka et al., 2011). Despite fibrosis
being an assumed part of aging, it has long been established that increased fibrosis, and particularly
perivascular fibrosis, is observed in hypertrophic hearts within the elderly population (Okada et
al., 1986), Comparison of fibrosis between our control heart and pathologic samples confirmed
increased fibrosis in diseased hearts, suggesting that these individuals possessed impaired
contractility consistent with gross observation. Additional histologic features observed in these
donors which were suggestive of heart disease included: the presence of discoloration to the
myocardium following trichrome staining (Ouyang et al., 2010), cardiac lipomatosis (Patra et al.,
2013; Matsuo et al., 2013; Anumonwo et al., 2018), cardiomyocyte alterations (Radu et al., 2012),
and the presence of increased myocardial angiogenesis (Hudlicka, 1982; Toyota et al., 2004;
Robich et al., 2011).
Based on these histologic results, it was determined that many cadaveric donors possess
evidence of undocumented heart disease, but that gross measurements are insufficient for the
detection of heart disease. In several cases, hearts possessing documented heart disease had normal
ventricular measurements, and in other cases, hearts with normal measurements and no
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documented heart disease possessed histologic features comparable with those of donors with
confirmed heart disease.

This correlates with previous studies which presented evidence

suggesting that severe heart disease is not always associated with a corresponding increase in
ventricular thickness (Olivotto et al., 2003). This supports the necessity of incorporating additional
diagnostic tests beyond echocardiography for the diagnosis of heart disease, and stresses the
importance of providing histologic confirmations in future studies assessing heart disease in
cadaveric donors.

Undiagnosed heart disease and increased susceptibility to disease in the elderly
The fact that many of the individuals possessing undiagnosed heart disease in this study
were elderly presents a significant concern. Despite the reality that some level of cardiovascular
dysfunction is considered typical in the elderly, the pathologic features consistently detected in
this study are nevertheless significant because they place these individuals at increased risk of
disease. Previous studies in Austria revealed that 77% of unexpected out-of-hospital deaths in
patients over the age of 85 with an average age of 88 were caused by CVD (Berzlanovich et al.,
2003). This study also revealed that 31% of patients who died had previously been considered
healthy. This study reflects the reality that many forms of CVD may be undiagnosed, placing the
elderly population at a significant risk of sudden death—whether from CVD itself or because of
increased susceptibility to other diseases due to their compromised cardiovascular system.
Past studies have demonstrated that underlying CVD causes individuals to be particularly
vulnerable to other diseases (Fry et al., 2005; Corrales-Medina et al., 2010), as well as to certain
medications with CVD side effects (Page et al., 2016). In the absence of CVD diagnoses, these
individuals may not recognize their risk and take appropriate precautions, or medications might be
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administered without taking into account cardiovascular risk.
Based on our findings regarding the prevalence of undiagnosed heart disease within the
elderly population, it could be argued that most elderly individuals possess a compromised
cardiovascular system, making them highly susceptible to diseases that tax the cardiovascular
system such as bacterial and viral infections. Particularly noteworthy is how this undiagnosed
heart disease could place individuals at risk of contracting the recently discovered novel
coronavirus-19 (COVID-19) which has been found to be especially fatal within the elderly
population (Huang et al., 2020). Due to the increased burden placed on the cardiovascular system
by infection, those who possess compromised cardiovascular health have a weakened ability to
accommodate the increased strain on the heart and vasculature (Zheng et al., 2020). Studies in
recent months have already demonstrated that COVID-19 mortality is significantly higher in the
elderly population (Shi et al., 2020; Zhou et al., 2020) and it has become well-established that
underlying CVD causes patients to be at a far greater risk of mortality following infection with
COVID-19 (Clerkin et al., 2020; Schaller et al., 2020; Zheng et al., 2020). While only a percentage
of individuals dying from COVID-19 are thought to possess CVD, it is possible that many of the
remaining coronavirus-related deaths also had CVD involvement which was unknown before
death and undiscovered after death—a possibility made even more likely by the fact that autopsy
rates are particularly low in COVID-19 patients (Salerno et al., 2020). In order to prevent
increased mortality by infectious diseases such as COVID-19, it is imperative that underlying CVD
be diagnosed and addressed so that high-risk individuals—both elderly and otherwise—can
implement preventative measures, and so that clinicians can more effectively treat these diseases
in light of the knowledge of underlying CVD involvement.
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Undiagnosed heart disease and genetic susceptibility of relatives
In addition to placing members of the elderly population at significant unknown risk of
disease, the possibility of undiagnosed heart disease in these individuals is significant since many
forms of heart disease are familial in nature and therefore were likely passed on to future
generations unaware of their risk for developing heart disease (Pan et al., 2012; Chiu et al.,
2010). Hypertrophic and dilated cardiomyopathies are two forms of familial heart disease which
are inherited in an autosomal dominant manner and are associated with many genetic variants
affecting cytoskeletal and sarcomeric proteins (McNally and Mestroni, 2017; Alcalai et al., 2008;
Ren et al., 2018). Without knowledge of their predisposition towards heart disease, individuals
may remain ignorant of these diseases in their early stages when preventative measures would be
most effective (Miller et al., 2014). In order to facilitate methods of early diagnosis and treatment,
individuals must be aware of the genetic predispositions they possess; ignorance may contribute
to increased incidence of heart disease-related death and disability.

Conclusion
These findings indicate that in the absence of an autopsy, many forms of heart disease
remain undiagnosed. While only 1 in every 4 individuals is thought to possess heart disease as an
underlying cause of death (Virani et al., 2020), many individuals in the remaining population may
unknowingly possess advanced forms of heart disease, particularly within the elderly and female
populations.

In order to effectively protect this vulnerable portion of the population,

cardiovascular conditions must be revealed, and cardio-protective therapies incorporated.
Additionally, due to the genetic nature of many types of heart disease, these individuals may also
have unknowingly passed genetic predispositions on to future generations. In order to facilitate
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early intervention and treatment in affected descendants, it is important that these potentially
genetic conditions be identified and documented.

Limitations
Cadaveric studies inherently possess certain limitations due to natural changes that occur
following fixation, limited access to complete donor information, and a natural bias towards the
elderly population.

Previous studies have demonstrated that cardiac chamber size may be

influenced by age, gender, height, and weight (Pfaffenberger et al., 2013) and additional studies
have indicated that cardiomyocyte size may also be influenced by height and weight (Tracy and
Sander, 2011). These variables were not assessed in our analysis of the cadavers in this study, and
it is possible that ventricular thickness or the size of the cardiomyocytes may have been influenced
in some cases by these factors, although many studies have confirmed the reliability of cadaveric
tissue for identification and characterization of pathology (Wood et al., 2015; Rae et al., 2018).
Beyond this, since many donors possess advanced medical conditions, it is important to
consider that heart conditions may be caused by the drugs or therapies used to treat noncardiovascular conditions. Radiation treatments, chemotherapy, and other anti-cancer drugs are
known to increase later risk of CVD (Aleman et al., 2014), making it possible that some of the
cases of CVD observed in cadaveric donors are due to treatments the donor received for unrelated
conditions. Our assessment of CVD in this population of cadaveric donors was focused on
overarching prevalence of CVD and did not include an in-depth assessment of additional medical
conditions or causes of death which may have influenced the individual’s propensity towards
CVD. In addition, since medical records may be inaccurate or incomplete (Coradazzi et al., 2003;
Shojania et al., 2003), past conditions requiring chemotherapy, radiation, or other CVD-promoting
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treatments may not be documented, but nevertheless may have triggered the eventual development
of CVD in these patients. However, studies have also shown that patients already possessing CVD
risk factors have a greater risk of developing CVD following exposure to these treatments
compared to individuals lacking characteristic CVD risk factors (Aleman et al., 2014). While the
cancer treatment may have been the initial catalyst for the development of CVD, the presence of
preexisting risk factors would have provided the initial susceptibility. Therefore, it is nevertheless
important in these cases to identify genetic risk factors, so that family members are aware of their
propensity—not merely towards primary CVD—but also towards specific CVD-related side
effects of medications or therapies.
Our studies were also limited by restricted access to donor records. While documentation
provided with cadaveric donors includes stated COD on death certificate as well as additional
health information provided by general practitioner or family members, these records may not
always be complete. For example, donors with pacemakers or evidence of coronary bypass
surgery were not always documented as such in medical records. For our study, these patients
were classified as possessing diagnosed CVD, but the absence of these conditions in documented
records leaves some room for question as to whether additional known conditions might also have
been excluded. Furthermore, recent studies have demonstrated an overrepresentation of certain
disease classes, including CVD, in medical records for cadaveric donors compared to the general
population (Collins et al., 2018), making it possible that these diseases might be more prevalent in
those choosing to donate their bodies. This does not negate the value of studying disease burden
within the cadaveric population, but suggests that results may be slightly biased towards certain
disease classes.
An additional limitation of this study is the restricted population demographic represented.
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Race and socioeconomic status were not included in our analysis, although these factors are also
known to influence CVD risk (Erqou et al., 2018; Xiao et al., 2018). Minorities are often
underrepresented in anatomical donor programs (Asad et al., 2014; Collins et al., 2018), making it
difficult to provide a thorough assessment of disease prevalence in these individuals through the
means of cadaveric studies. Future studies should examine prevalence of undocumented CVD in
individuals of different races and socioeconomic backgrounds.
In addition, it is known that the cadaveric donor population is often biased towards elderly
individuals (Cornwall et al., 2012; Collins et al., 2018), which was also the case in the cadaveric
donors assessed in this study. This factor makes it difficult to determine the extent of correlation
between these results and the general population. Further studies should attempt to specifically
examine the gross anatomy and histology of hearts from middle-aged individuals in order to
determine the extent of undiagnosed heart disease in the middle-aged population. However,
despite limited applicability to the rest of the population, studies that specifically assess
undiagnosed heart disease in the elderly population are necessary given the significant implications
for susceptibility to disease and the corresponding healthcare burden associated with this risk.
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CHAPTER 3

Extraction of Amplifiable RNA from Cadaveric Donor Hearts for the
Identification of Genetic Risk Factors for Heart Disease

*Dr. Gary Isaacs contributed to this work by performing R studio analyses
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Summary
Heart disease has long been the leading cause of death in the US, causing hundreds of
thousands of deaths annually and serving as a source of disease-related morbidity for millions
more. However, it has been suggested that many cases of heart disease may remain unknown after
death since autopsy—the gold standard in detecting the exact cause of death and additional
pathologies—is only performed in 8% of deaths in the US. This has significant implications for
surviving family members since many forms of heart disease possess genetic components.
Previous studies have demonstrated the extensive prevalence of undocumented heart disease in
cadaveric donors, but there is no means of ascertaining whether these pathologies are connected
to differential expression of genetic risk factors since there is currently no protocol for RNA
extraction from embalmed cadaveric tissue. In this study, we present an RNA extraction protocol
modified for embalmed human cadaveric tissue for the purpose of identifying genetic risk factors
related to heart disease. These findings demonstrate that—despite degradation resulting from
formalin fixation—amplifiable RNA from human cadaveric heart tissue can be successfully
extracted and used to identify genetic risk factors for heart disease through gene expression
analysis. These results provide a route by which embalmed tissue can be utilized for identification
of genetic risk factors and for study of genetic changes associated with the wide range of
pathologies observed in cadaveric donors.

Introduction
Cardiovascular disease (CVD) has long been the leading cause of death (COD) both
nationally and globally (Greenlund et al., 2006), with over 850,000 individuals in the US and 17.8
million individuals worldwide dying of CVD annually (Virani et al., 2020; Heron, 2019). CVD
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encompasses a wide spectrum of heart and vasculature-related disorders, including heart disease,
stroke, atherosclerosis, coronary artery disease, arrhythmias, thromboembolisms, and others
(Mensah et al., 2007; Virani et al., 2020). Heart disease specifically has served a particularly
severe role in US morbidity and mortality, alone causing more deaths than cancer—the second
leading COD in the country (Heron, 2019)—and resulting in significant disability for the estimated
30.3 million adults living with various forms of heart disease (Pellicori et al., 2015; Centers for
Disease Control and Prevention, 2018a; Virani et al., 2020).
Prevalence of heart disease varies significantly by age, with the elderly being particularly
susceptible due to changes that occur in the heart with age, coupled with accumulation of CVD
risk factors (Dhingra et al., 2012). However, while approximately 12% of the adult US population
is estimated to possess diagnosed heart disease (Centers for Disease Control and Prevention,
2018a), studies have suggested that these values may be even higher than what is reported due to
the possibility of undiagnosed CVD in the population—CVD that is undetected during life due to
the absence or atypical presentation of symptoms (Quinn et al., 2017; Reynolds et al., 2019) and
remains unknown even after death due to the absence of autopsy (Friberg et al., 2019).
Previous studies have revealed that many pathologies remain undiagnosed in the absence
of autopsy examination (Kuijpers et al., 2014; Mieno et al., 2016; Euler et al., 2017; Friberg et al.,
2019), with CVD in particular being a commonly underdiagnosed condition (Sington et al., 2002;
Roulson et al., 2005; Ravakhah, 2006; Tavora et al., 2008b; Mieno et al., 2016; Friberg et al.,
2019) and discrepant CVD findings more frequently occurring in the elderly (Saad et al., 2007).
The possibility that undiagnosed CVD could persist in the absence of an autopsy is concerning
considering that only 8% of deaths in the US receive an autopsy and these rates are even lower in
the elderly (Hoyert, 2011; Goldman, 2018). This suggests a strong potential for undiagnosed CVD
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in non-autopsied individuals, a possibility that has implications for those living today since many
forms of CVD are associated with significant genetic components (Keating et al., 1996; Ehret et
al., 2011; Pan et al., 2012). If individuals die with undiagnosed disease, their family members may
possess genetic risk factors which could likewise remain unknown until the occurrence of a
cardiovascular event (Quinn et al., 2017; Reynolds et al., 2019).
It has been proposed, however, that the high rates of discrepancy observed in death
certificates are due to a natural selection bias towards cases prone to error, since the ambiguity of
the COD was the very reason these cases were referred for autopsy (Tavora et al., 2008a). While
this has not been supported by studies in hospitals with high autopsy rates—where a lesser
potential for selection bias would be expected (Shojania et al., 2003)—the more significant
question is whether additional pathologic findings not contributing to COD might be missed even
when COD is correct. Elderly individuals frequently possess multiple comorbidities (Gill et al.,
2013), a factor which is reported to cause difficulty in making accurate heart disease diagnoses
(Lien et al., 2002). Consistent with these reports, autopsy studies have also revealed significant
prevalence of undocumented disease beyond what is related to the individual’s COD (Euler et al.,
2017; Friberg et al., 2019). However, since these studies were performed in individuals receiving
an autopsy, the question remains as to whether discrepant findings would manifest in the rest of
the population as frequently as they are found in autopsied individuals.
Cadaveric donors provide a unique means of studying disease prevalence in the general
population since none of these individuals receive an autopsy prior to death. While it has been
reported that certain biases still exist within the cadaveric population, including a bias towards
donors possessing CVD according to documented records (Collins et al., 2018), these donors are
still close to being representative of the vast majority of individuals in the population who never
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receive an autopsy after death. Cadavers provide an extensive and largely untapped data pool
(MacBride, 1998) for the study of undocumented pathologies since the dissection process affords
the opportunity for thorough examination of various organ systems in a manner that is impossible
in living subjects.
Many cadaver-based studies have demonstrated an abundance of pathology, both
documented and undocumented (Chun et al., 2007; Wood et al., 2010; Plummer et al., 2018). Our
own studies have confirmed these findings, revealing a significant percentage of cadaveric donors
possessing undocumented CVD and, in particular, severe undocumented forms of heart disease
(Passburg et al., 2019). Our studies demonstrated these findings in both male and female donors,
but it was found that female donors were more likely than males to possess undocumented heart
disease.
It is possible that these undocumented findings could be correlated with genetic risk
factors, but embalmed tissue has not been used in the past for genetic studies due to significant
formaldehyde-induced crosslinking (Hoffman et al., 2015) and the subsequent degradation of
genetic material associated with this process (Okello et al., 2010; Eltoum et al., 2013).
Despite these limitations, previous studies have demonstrated the ability to extract
amplifiable DNA from embalmed cadaveric tissue and utilize this genetic material to genotype
donors and reveal certain isoforms associated with increased risk of disease. However, while DNA
is useful for identification of genetic risk factors, there are limitations to this technique; namely,
the reality that the presence of a gene does not guarantee the expression of that gene (Adams,
2008). The most effective means of identifying genes implicated in disease progression is through
gene expression profiling, a technique which requires the extraction of RNA (Seo et al., 2006).
However, there currently exists no successful protocol for the extraction of RNA from
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cadaveric donors. Our study is the first to present a method for extraction of amplifiable RNA
from formalin-fixed cadaveric tissue. It is also the first to demonstrate the successful use of this
method for yielding RNA viable for microarray analysis and identification of differential gene
expression patterns associated with heart disease.

Materials and Methods
Cadaver Preservation and Tissue Extraction
Cardiac muscle tissue samples were taken from 29 cadaveric donors routinely utilized for
gross anatomy labs at Liberty University in Lynchburg, VA. Cadavers were embalmed at donor
facilities using a two-site injection method within 24 hours of death with a neutral buffered
formalin solution consisting of 48.59% ethanol, 20.00% formaldehyde, 14.79% ethylene glycol,
11.00% phenol, and 4.80% glutaraldehyde. Cadavers were stored in ventilated stainless-steel
tanks in non-porous body bags and kept moist as needed with wetting solution (Carolina Biological
Supply Co.; Burlington, NC).

Diseased and normal hearts were classified based on gross

parameters for heart disease utilized in previous cadaveric studies (Rae et al., 2017; Passburg et
al., 2019). The time elapsed between death and time of tissue isolation varied between cadavers,
but tissue samples were isolated from the left ventricle of donor hearts within 2-7 months postmortem and stored in neutral-buffered formalin. RNA extraction was performed within 1-5 weeks
of tissue collection.

RNA Isolation
RNA was isolated from heart samples by combining an RNA isolation procedure for
formalin-fixed, paraffin-embedded lymphatic tissue (Korbler et al., 2003) with a Trizol-based
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phenol-chloroform extraction protocol (Invitrogen Corporation; Carlsbad, CA). Formalin-fixed
tissue was isolated and processed directly from the cadaveric donors without any prior paraffin
embedding steps so that larger quantities of tissue could be processed without the damage
frequently associated with the paraffin-embedding process and subsequent extraction (Kashofer et
al., 2013). Deparaffinization and rehydration steps were eliminated, and processing of tissue
samples began with direct isolation of formalin-fixed tissue (200-280 mg) and homogenization in
100% 200-proof ethanol. The homogenate from each sample was equally divided between two
eppendorfs to accommodate the appropriate reagent volumes for the amount of tissue being
processed; RNA samples from the same donor hearts were later recombined in the final
resuspension step. Each pellet was isolated and resuspended in a digestion buffer containing
10mM NaCl, 500mM Tris (pH 7.6), 20mM EDTA, and 1% SDS. 500µg/ml RNA grade proteinase
K (Thermofisher; USA) was added and the solution was incubated at 45°C for 16-20 hours to
remove protein-RNA crosslinking.

Following incubation, a standard Trizol-based phenol-

chloroform extraction was performed. Trizol reagent (Thermofisher; USA) was added to each
pellet and incubated for 10 minutes at room temperature, followed by addition of chloroform and
a 5-minute incubation period. The upper RNA-containing aqueous phase was isolated by a 30minute centrifugation at 12,000g at 4°C and transferred to a fresh tube to be mixed with chilled
isopropanol. The solution was incubated at -20°C for 2 hours to precipitate the RNA, followed by
a 4°C centrifugation at 12,000g for 10 minutes. The pellet was washed in chilled 75% ethanol,
air-dried, and pellets from the same donor hearts were resuspended together in 20-30µl RNasefree water. Yield and purity were measured by nanodrop spectrophotometry (ND-2000, Nanodrop
Technologies). Resuspended RNA samples were stored at -80°C until being utilized for cDNA
synthesis.
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Reverse transcription and PCR amplification
RNA was reverse-transcribed using 1µl MuLV reverse transcriptase enzyme mix in
reaction buffer mix containing deoxyribonucleotide triphosphates (dNTPs), random octamers, and
oligo dT-16 (Applied Biosystems, Foster City, CA). Approximately 1-1.2µg of RNA was used
per reaction in a total volume of 20µl. The reaction was incubated in a thermal cycler at 37°C for
60 minutes, followed by an inactivation step at 95°C for 5 minutes. A total of 5µl of cDNA from
each reverse transcription reaction was subsequently utilized in PCR amplification of the housekeeping genes β-actin and GAPDH and the cardiac-specific gene cardiac troponin T (cTnT).
Primers spanning an intron were utilized in order to detect amplification of possible DNA
contamination in RNA samples. The 205bp GAPDH, 189bp β-actin, and the 152bp cTNT
products were amplified using the primers 5’-ggatttggtcgtattggg-3’ and 5’-ggaagatggtgatgggat-3’,
5’-caccaactgggacgacat-3’ and 5’-acagcctggatagcaacg-3’, and 5’-ggcagcggaagaggatgctgaa-3’ and
5’-gaggcaccaagttgggcatgaacga-3’, respectively (IDT, Coralville, IA). PCR reactions utilized
DreamTaq Polymerase (Thermo Scientific, USA) in a final reaction volume of 50µl. PCR was
performed in a thermal cycler with the following parameters: for GAPDH, 30 seconds at 95°C, 30
seconds at 51.8°C, 30 seconds at 72°C; for β-actin, 30 seconds at 95°C, 30 seconds at 56°C, and
30 seconds at 72°C; and for cTnT, 30 seconds at 95°C, 30 seconds at 62°C, and 30 seconds at
95°C. Each PCR reaction included an initial 3-minute denaturation step at 95°C and a final 5minute extension step at 72°C. Product amplification was confirmed through gel electrophoresis
utilizing a 1% agarose gel with ethidium bromide.

Microarray Analysis
Based on previous research demonstrating that cardiac transcriptome profiles differed
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significantly between males and females (Trexler et al., 2017), RNA samples selected for
microarray analysis were taken exclusively from 13 female cadavers, all of which had displayed
successful amplification of GAPDH. A minimum of 4µg of RNA was submitted for each sample
with an average 260/280 ratio of 1.82 for the 13 samples. The selected samples included 6 taken
from donors possessing documented forms of CVD, 6 from donors possessing features consistent
with undocumented heart disease, and 1 heart possessing normal values for ventricular thickness.
It was noted, however, that one of the 6 undiagnosed CVD samples possessed a documented
nontraumatic cerebral hemorrhage—a condition which may or may not be due to CVD-related
causes; therefore, while this donor was classified as one of the undiagnosed CVD samples, it is
possible that there were in fact CVD-related causes to this donor’s medical history. While only 2
of the donors classified as possessing documented CVD also possessed documented heart disease,
these individuals were grouped together as a single class since many forms of CVD are
interconnected. Heart disease is a known risk factor for stroke and other peripheral vascular forms
of CVD (Adelborg et al., 2017), making it likely that these individuals might possess similar
patterns of differential gene expression even though their respective forms of CVD varied. Due
to the shortage of healthy hearts, control samples were limited to RNA taken from a single heart
which did not possess CVD according to documented records and possessed ventricular thickness
measurements consistent with normal heart standards. It was noted, however, that histologic
examination of this heart revealed extensive fibrosis, a pathologic feature often associated with
heart disease (Wolf et al., 2005; Camelliti et al., 2005; Espeland et al., 2018), although not
guaranteed to be genetic.
All procedures for RNA quality control (QC) and gene expression analysis for the 13
samples submitted for microarray were conducted by Arraystar Inc. Total RNA from each sample
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was quantified by NanoDrop ND-1000 and RNA integrity was assessed by 1.2% denaturing
agarose gel electrophoresis with formaldehyde and SYBR green in 1x Tris-acetate-EDTA stained
with ethidium bromide. Samples were amplified and transcribed into fluorescent cRNA along the
entire length of the transcripts without 3’ bias utilizing a random priming method (Arraystar Flash
RNA Labeling Kit, Arraystar). The labeled cRNAs were hybridized onto the Human LncRNA
Array v5.0 (8 x 60K, Arraystar) which is capable of detecting 39,317 lncRNAs and 21,174mRNAs.
After washing the slides, the arrays were scanned by the Agilent Scanner G2505C.
Quantile normalization and subsequent data processing were performed by Arraystar Inc
using GeneSpring GX v12.1 software package (Agilent Technologies).

After quantile

normalization of the raw data, mRNAs that had flags in Present or Marginal intensities in at least
1 out of 13 samples were chosen for differentially expressed mRNA screening. Differentially
expressed mRNAs with statistical significance were identified by performing fold change filtering
between the 2 compared sample groups. Fold change between log2 transformed normalized
intensities was calculated with the following equation where norm1 and norm0 indicate
normalized intensities for the two compared samples:
𝐹𝐹𝐹𝐹 = 2|𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛1−𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛0|

Hierarchical clustering and heat map analysis of differentially expressed genes was
performed by Arraystar Inc. to identify variations in patterns of differential gene expression in
diagnosed CVD samples compared with undiagnosed CVD samples.

Statistical Analysis
Spearman correlation tests were used to calculate statistical significance of correlations
between group variables. Unpaired, two-tailed student t-tests were used to calculate statistical
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significance of variations between samples.
Number of unique transcripts detected for each sample and between all 13 samples was
determined with R studio. Analysis of differentially expressed genes only took into account genes
detected in all 13 samples. Statistical significance of differentially expressed genes in diagnosed
and undiagnosed CVD groups was determined by performing one-sample t-tests for genes
displaying a fold change of 2 or more between the control sample and experimental groups. Onesample t-tests compared average normalized intensity of experimental groups with the normalized
control intensity, and genes were ranked based on fold change and p value. Genes displaying a
fold change of 2 or more and a p value <0.05 were classified as genes displaying significant
differential expression between the control sample and experimental groups.

Results
High yield RNA extraction from cadaveric donor hearts
RNA yield between cadaveric hearts ranged from 42.9 ng/µl to 504.8 ng/µl, with an
average yield of 274.29 ng/µl. The average 260/280 ratio was 1.82 and the average 260/230 ratio
was 0.87, indicating some level of contamination but sufficient purity for PCR and microarray
analysis (Table 3.1). Among the 13 hearts selected for microarray analysis, the average yield was
292.55 ng/µl and average 260/280 and 260/230 ratios were 1.82 and 0.88, respectively. However,
QC reports from microarray analysis for these samples demonstrated higher 260/280 and 260/230
ratios and lower yield than initial calculations had suggested. QC reports from Arraystar Inc
indicated an average yield of 199.90 ng/µl, an average 260/280 ratio of 1.92, and an average
260/230 ratio of 1.92, indicating lower yield, but higher purity than was previously suspected.
Denaturing agarose gel electrophoresis of the 13 RNA samples submitted for microarray analysis
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Tissue

Yield (ng/µl)

260/280

260/230

Total Hearts
(n=29)

274.29 (± 114.62)

1.82 (± 0.05)

0.87 (± 0.33)

Female Hearts
for Microarray
Analysis (n=13)

292.55 (± 83.37)

1.82 (± 0.04)

0.88 (± 0.29)

Arraystar QC
Results for
Female Hearts
(n=13)

199.90 (± 73.62)

1.92 (± 0.05)

1.92 (±0.26)

Table 3.1 Quantification and absorbance ratios for RNA obtained from cadaveric donor
hearts.
RNA extraction from 29 cadaveric donor hearts demonstrated a range of yield and purity ratios,
but results indicated that the majority of samples yielded sufficient quantity and purity for
downstream applications. Also listed here are values for female hearts chosen for microarray
analysis, including both initial values, as well as those obtained during QC analysis by Arraystar
Inc. QC analysis revealed lower yield, but higher purity than was previously suspected.
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revealing smearing of the RNA and did not generate sharp 28S and 18S ribosomal bands (Figure
3.1), but these patterns of degradation are consistent with formalin-fixed RNA samples (Zhang et
al., 2010).
Comparison of RNA yield and purity between samples collected at varying post-mortem
intervals did not appear to be significantly influenced by the length of the post-mortem interval
within the ~7-month range represented here. Likewise, duration between sample isolation and
RNA extraction was not significantly correlated with variations in RNA yield or purity based on
Spearman’s correlation coefficient analysis. Past studies have demonstrated that post-mortem
interval can negatively affect DNA yield and quality from embalmed cadaveric tissue (Gielda et
al., 2017), but no statistically significant relationship between postmortem interval and RNA yield
or purity was observed within the 7-month timeframe encompassed by this study. However, it is
important to note that studies demonstrating this relationship were comparing cadavers whose
postmortem intervals varied by a year or more; future studies should assess the effects of prolonged
fixation over the course of a year or more on RNA quality.

Housekeeping and heart-specific genes can be amplified from embalmed cadaveric RNA
cDNA synthesis and PCR of the standard housekeeping genes β-actin and GAPDH
demonstrated that the 205bp GAPDH fragment possessed a significantly higher amplification rate
than that of β-actin. Minimal amplification of the 189bp β-actin transcript was observed, but
rather, over half of the samples displayed amplification of the 630bp genomic DNA product,
indicating contamination in many of these samples (Figure 3.2). While a certain level of genomic
contamination was also observed for GAPDH, the 205bp GAPDH transcript was successfully
amplified in 97% of the samples tested (Figure 3.3). However, while few samples displayed
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Figure 3.1 RNA integrity tested by denaturing agarose gel electrophoresis for 13
cadaveric RNA samples.
QC analysis for the 13 RNA samples chosen for microarray analysis was performed by
Arraystar Inc through denaturing 1.2% agarose gel electrophoresis with formaldehyde and
SYBR green in 1X Tris-acetate-EDTA. This analysis revealed the absence of sharp ribosomal
RNA bands, indicating RNA degradation. However, these results are not unusual for
formalin-fixed RNA samples (Zhang et al., 2010).
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amplification of the 189bp β-actin product, microarray analysis detected β-actin transcripts in all
13 samples submitted for microarray analysis, including those previously lacking evidence of βactin amplification by gel electrophoresis.
Amplification of cTnT displayed a lower amplification rate than GAPDH, with only 55%
of samples displaying successful amplification (Figure 3.4). However, this transcript was detected
in all samples submitted for microarray analysis, even those which had previously not displayed
successful cTnT amplification. Correlation tests between amplification success and intensity of
cardiac troponin T based on microarray analysis revealed that samples failing to display successful
amplification of the gene displayed significantly lower intensities based on normalized microarray
values (p=0.003). This suggests that failed amplification may not be due to degradation of the
transcript, but rather a possible down-regulation of cardiac troponin levels in those particular heart
samples.

Cadaveric RNA can be utilized for microarray analysis
Microarray analysis revealed 11,342 unique mRNA transcripts which were detected in at
least 1 of the 13 samples. However, the number of transcripts consistently detected in all 13
samples was much lower, with only 6,561 transcripts detected in all samples (Figure 3.5; Table
3.2). Detection rates varied significantly from one sample to the next, with donor 9 possessing the
lowest (7,227 transcripts) and donor 6 displaying the highest detection success (10,344 transcripts).
Analysis of differentially expressed genes between control and diseased samples revealed
altered expression of genetic risk factors for heart disease both in samples from donors with
diagnosed CVD and in those possessing features suggestive of undiagnosed CVD. Genes that
fulfilled the criteria of a rank change equal to 2 or more and a one-sample t-test p-value <0.05
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Figure 3.2 RT-PCR of β-actin visualized by 1% agarose gel electrophoresis in 16
cadaveric donor hearts.
β-actin PCR resulted in minimal amplification of the 189bp product. Bands depicting a
fragment size of 630bp indicated genomic DNA contamination, suggesting that approximately
59% of cadaveric RNA samples possessed significant genomic contamination (data for
remaining 13 samples not shown). Control sample contained all PCR reagents except for the
cDNA template and was processed through the same thermal cycler parameters for β-actin as
samples containing cDNA template.
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Figure 3.3 RT-PCR of GAPDH visualized by 1% agarose gel electrophoresis in 29
cadaveric donor hearts.
GAPDH amplification revealed successful amplification in all except for 1 of the 29 extracted
RNA samples. Donor 1 did not display amplification in these results, but successful
amplification was demonstrated from GAPDH amplified in a separate PCR run (data not
shown). Bands depicting a fragment size of 295bp and 204bp indicated genomic DNA
contamination. The 204bp genomic DNA fragment may have partially obscured the 205bp
product, but the minimal presence of genomic DNA contamination at the 295bp level indicates
that the strong 205bp band is primarily due to amplification of the GAPDH transcript rather
than genomic DNA contamination. Control sample contained all PCR reagents except for the
cDNA template and was processed through the same thermal cycler parameters for GAPDH as
samples containing cDNA template.
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Figure 3.4 RT-PCR of cTnT visualized by 1% agarose gel electrophoresis in 18 cadaveric
donor hearts.
Amplification of the 152 bp cTnT PCR product displayed variable amplification between
samples, with successful amplification being observed in 55% of extracted RNA samples (data
for remaining 11 samples not shown). Control 1 contained all PCR reagents except for the
cDNA template and control 2 only contained primers and RNase-free water. All control
samples were processed through the same thermal cycler parameters for cTnT as samples
containing cDNA template.
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Figure 3.5 Detection of unique mRNA transcripts by microarray analysis in 13 RNA
samples extracted from embalmed cadaveric heart tissue.
Microarray analysis revealed that out of the 14,409 genes comprising the cardiac
transcriptome, 11,342 unique mRNA transcripts were detected in at least 1 of the 13 RNA
samples. Significant variability in individual transcript detection was observed, but a total of
6,561 unique mRNA transcripts were consistently detected in all 13 samples.
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Detected in one or more samples (n=13)
Detected in all samples (n=13)
Control – Donor 1
Diagnosed CVD – Donor 2
Diagnosed CVD – Donor 3
Diagnosed CVD – Donor 4
Diagnosed CVD – Donor 5
Diagnosed CVD – Donor 6
Diagnosed CVD – Donor 7
Undiagnosed CVD – Donor 8
Undiagnosed CVD – Donor 9
Undiagnosed CVD – Donor 10
Undiagnosed CVD – Donor 11
Undiagnosed CVD – Donor 12
Undiagnosed CVD – Donor 13

# of unique mRNA transcripts
detected (% of cardiac
transcriptome)
11342 (78.7%)
6561 (45.5%)
9394 (65.2%)
9321 (64.7%)
8288 (57.5%)
9126 (63.3%)
7523 (52.2%)
10344 (71.8%)
7545 (52.4%)
8814 (61.2%)
7227 (50.2%)
9108 (63.2%)
8613 (59.8%)
8992 (62.4%)
8205 (56.9%)

Table 3.2 Number of unique mRNA transcripts detected by microarray analysis in 13
RNA samples extracted from embalmed cadaveric heart tissue.
Detection of unique transcripts varied between samples, with values ranging from 7,227 to
10,344 depending on the specific sample assessed. 11,342 unique transcripts were detected in
one or more samples, but only 6,561 unique transcripts were detected in all 13 samples. This
indicates that many transcripts expressed in the heart can be detected and that over half of these
are consistently detected regardless of donor-specific variations, but that certain transcripts are
not consistently detected in all donors.
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revealed 17 genes that were up-regulated and 67 genes that were down-regulated in the diagnosed
CVD samples compared with the control and 100 genes that were up-regulated and 125 genes that
were down-regulated in undiagnosed CVD samples. Out of the genes displaying differential
expression in the diagnosed CVD samples, 11 were associated with various forms of heart disease
(Table 3.3). Analysis of differentially expressed genes in the undiagnosed CVD samples revealed
16 genes known to be associated with heart disease (Table 3.4).
Comparison of gene expression between diagnosed CVD samples and undiagnosed CVD
samples revealed that diagnosed CVD samples clustered together and undiagnosed CVD samples
formed a separate cluster, with the exception of donor 8—an undiagnosed CVD sample which
clustered with the diagnosed CVD donors (Figure 3.6). However, donor 8 possessed a documented
condition that could have had possible CVD involvement, providing a possible explanation for its
closer association with diagnosed CVD samples.

Discussion
Heart disease is a prevalent concern in the US, causing hundreds of thousands of deaths
and afflicting millions more with disease-related disability (Virani et al., 2020). Of increasing
concern, however, is the reality that many individuals could possess undiagnosed heart disease
which remains unknown even after death. Since many forms of CVD are genetic (Keating et al.,
1996; Ehret et al., 2011; Pan et al., 2012), undiagnosed disease in these individuals may be
correlated with heritable risk factors which have unknowingly been passed down to subsequent
generations (Tavora et al., 2008b). Our studies have revealed that many manifestations of heart
disease are undocumented within the cadaveric population and particularly within female donors
(Passburg et al., 2019), and it is likely that many of these cases, both known and unknown, could
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Differentially Expressed Genes in Diagnosed CVD vs Control
Gene
Code

Description

Fold
Change

Regulation

P-value

Associated Diseases

GATA1

GATA binding protein 1

2.040514

Up

0.020946

Cardiac Arrhythmia; Atrioventricular
Septal Defect

SOD3

Superoxide dismutase 3

3.914982

Down

0.00087

Heart failure; Hypertensive disease

SLC25A4

Solute carrier family 25
member 4

5.361156

Down

0.004565

Hypertrophic Cardiomyopathy; Diabetic
Cardiomyopathies

TPM3

Tropomyosin 3

5.650671

Down

0.005838

Dilated Cardiomyopathy

DES

Desmin

2.324794

Down

0.008715

Cardiac Arrhythmia; Dilated
Cardiomyopathy; Hypertrophic
Cardiomyopathy; Desmin-related
myofibrillar myopathy; Restrictive heart
failure; Left ventricular noncompaction

GSN

Gelsolin

8.092797

Down

0.009474

Cardiomyopathies; Acute Coronary
Syndrome

MYL2

Myosin light chain 2

8.330943

Down

0.009912

Hypertrophic Cardiomyopathy;
Ventricular Tachycardia; Left
ventricular septal hypertrophy

TNNC1

Troponin C1

6.090293

Down

0.01172

Dilated Cardiomyopathy; Hypertrophic
Cardiomyopathy; Left Ventricular
Noncompaction

ATP2A2

ATPase
sarcoplasmic/endoplasmic
reticulum calcium
transporting 2

3.837507

Down

0.012714

Heart Diseases; Cardiomegaly; Heart
failure; Myocardial Reperfusion Injury;
Myocardial Stunning; Left Ventricular
Dysfunction; Diabetic
Cardiomyopathies

CNNM2

Cyclin and CBS domain
divalent metal cation
transport mediator

2.788346

Down

0.015751

Cardiac Arrhythmia

MYL7

Myosin light chain 7

4.763219

Down

0.025701

Hypertrophic Cardiomyopathy
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Table 3.3 Differentially expressed genes in diagnosed CVD heart samples.
Comparison of diagnosed CVD heart samples with the control heart sample displayed
differential expression of 11 genetic risk factors associated with various forms of heart disease.
Genes possessing significant differential expression were defined as those possessing a fold
change greater than 2 compared with the control sample, and a one-sample t-test p-value of
<0.05 based on comparison of averaged normalized intensity of diseased samples with the
normalized intensity of the control sample.
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Differentially Expressed Genes in Undiagnosed CVD vs Control
Gene
Code

Description

Fold
Change

Regulation

P-value

Associated Diseases

GATA1

GATA binding
protein 1

2.420769

Up

0.000193

Cardiac Arrhythmia; Atrioventricular Septal
Defects; Cardiac conduction abnormalities

IL6

interleukin 6

2.803252

Up

0.013774

Atherosclerosis; Heart failure; Hypertensive
disease; Cardiovascular Pregnancy
Complications; Cerebrovascular accident;
Myocardial Ischemia; Left Ventricular
Dysfunction; Cardiomyopathies; Acute
Coronary Syndrome

POLG

DNA polymerase
gamma, catalytic
subunit

2.085465

Up

0.021645

Dilated Cardiomyopathy; Mitral Valve
Insufficiency;itral Valve Prolapse Syndrome

EDN3

endothelin 3

2.219301

Up

0.033282

Cardiovascular Diseases; Hypertensive
disease; Hypotension; Cardiovascular
Abnormalities; Bradycardia

PGM1

phosphoglucomutase
1

2.361358

Up

0.045294

Myocardial Ischemia

DNM1L

dynamin 1 like

2.489939

Up

0.048306

Myocardial Ischemia

HIRA

histone cell cycle
regulator

2.179434

Up

0.005101

Atrial Septal Defects; Ventricular Septal
Defects; Tetralogy of Fallot; Abnormality of
aortic arch; Abnormality of pulmonary valve

TMEM43

transmembrane
protein 43

2.416491

Down

0.005101

Sudden Cardiac Death; Familial
Arrhythmogenic right ventricular dysplasia

GYG1

glycogenin 1

2.719506

Down

0.005101

Cardiac Arrhythmia; Right bundle branch
block; Myocardial Ischemia

UTS2

urotensin 2

2.70239

Down

0.005101

Hypertensive disease; Bradycardia

CAV1

caveolin 1

2.089783

Down

0.005101

Atrial Fibrillation; Hypertrophic
Cardiomyopathy; Cardiomegaly;
Hypertensive disease; Pulmonary
Hypertension

GGT1

gammaglutamyltransferase
1

2.030943

Down

0.005101

Myocardial Infarction

MYLK2

myosin light chain
kinase 2

2.411669

Down

0.005101

Familial Hypertrophic Cardiomyopathy

GSN

Gelsolin

7.162524

Down

0.005101

Cardiomyopathies; Acute Coronary
Syndrome

NOS1AP

nitric oxide synthase
1 adaptor protein

2.566455

Down

0.005101

Variation in QT Interval; Heart conduction
disease

IGBP1

immunoglobulin
binding protein1

2.657641

Down

0.005101

Patent ductus arteriosus; Ventricular Septal
Defects
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Table 3.4 Differentially expressed genes in undiagnosed CVD heart samples.
Comparison of undiagnosed CVD heart samples with the control heart sample displayed
differential expression of 16 genetic risk factors associated with various forms of heart disease.
Genes possessing significant differential expression were defined as those possessing a fold
change greater than 2 compared with the control sample, and a one-sample t-test p-value of
<0.05 based on comparison of averaged normalized intensity of diseased samples with the
normalized intensity of the control sample.
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Figure 3.6 Hierarchical clustering and heat map analysis for differentially expressed
mRNAs in undiagnosed CVD samples compared with diagnosed CVD samples.
Comparison of differentially expressed genes in diagnosed CVD samples compared with
undiagnosed CVD samples displayed distinct patterns of gene expression in the two
experimental groups. Diagnosed CVD samples clustered together separately from undiagnosed
CVD samples, with the exception of donor 8. Donor 8 clustered with diagnosed CVD samples,
indicating gene expression patterns comparable to those of donors possessing documented
CVD. However, while donor 8 was classified as an undiagnosed CVD sample, this donor did
possess a documented cerebrovascular COD with possible CVD causation. These results
indicate that the cause of that condition was likely CVD based on the close similarity of gene
expression profiles, and provide a potential means by which samples with unknown or
uncertain CVD diagnoses can be correctly classified. In this heat map, “red” indicates high
relative expression and “green” indicates low relative expression, and the dendrogram
demonstrates the relationships among mRNA expression patterns of samples.
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be associated with genetic risk factors for heart disease.
Past studies have demonstrated that in order to accurately measure disease risk, it is
necessary to perform gene expression profiling utilizing extracted RNA (Kashofer et al., 2013).
While fresh frozen (FF) tissue is preferable for RNA extraction and gene expression analysis,
obtaining FF tissue is not always feasible, as was the case in our studies, and this serves as a
common limitation for many other studies as well (Mustafa et al., 2015). RNA has been routinely
extracted from formalin-fixed paraffin embedded (FFPE) samples for diagnostic and research
purposes (Kashofer et al., 2013; Haynes et al., 2018) and studies have demonstrated comparable
results between FFPE samples and FF samples (Mittempergher et al., 2011; Iddawela et al., 2016;
Bradley et al., 2015; Sapino et al., 2014). However, studies have demonstrated that shorter fixation
time for FFPE seems to correlate with better DNA/RNA extraction quality (Turashvili et al., 2012),
making it doubtful as to whether high quality genetic material could be extracted from embalmed
cadaveric tissue which might be preserved for months to years before extraction can occur. If
RNA could be extracted from cadaveric tissue and successfully utilized for genomic analysis, it
would open many avenues of research for case studies of disease pathogenesis and interactions, as
well as yield information which may be of critical value to existing family members who are
unaware of disease risk.
Recent studies by Gielda et al demonstrated that, despite formaldehyde crosslinking,
amplifiable DNA could be extracted from embalmed cadaveric tissue at sufficient yield and quality
for identification of genetic risk factors (Gielda et al., 2017).

These studies demonstrated

identification of genotypes corresponding to increased or decreased risk of Alzheimer’s disease
which accurately correlated with reported incidence or absence of dementia in medical records.
Furthermore, studies by Gerhard et al have demonstrated that DNA sequencing from human
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cadavers can be utilized to detect single nucleotide variants (SNVs). These SNVs were accurately
correlated with specific diseases documented in medical records such as ALS, cancer, and
Alzheimer’s disease (2016). These studies also demonstrated that cardiac muscle specifically
yielded large amounts of high molecular weight DNA viable for genomic analysis.
Until now, formalin-fixed cadaveric tissue has not been utilized for gene expression
analysis due to the extensive cross-linking and fragmentation of RNA associated with fixation—
factors which would potentially prevent the identification of specific genetic markers, particularly
those of large molecular weight (Okello et al., 2010; Kashofer et al., 2013). Our study is the first
to demonstrate the successful extraction and amplification of both systemic housekeeping genes
and cardiac-specific genes from embalmed cadaveric tissue. It is possible that some degradation
took place after death or during the RNA extraction process and that the severity of degradation
varied between donors depending on factors such as timing of initial preservation, success of
fixative infiltration, and disease state of various organs—factors which have been found to affect
histologic quality of tissue (Nicholson et al., 2005; Canene-Adams, 2013; Rae et al., 2018).
However, despite these factors, our results have demonstrated that genes ranging in size from
152bp to 205bp can be successfully amplified from cadaveric heart tissue.
Recently reported protocols for DNA extraction from cadaveric donors utilized a 95°C heat
extraction step rather than proteinase K digestion due to the fact that proteinase K digestion was
found to decrease yield and fragment size for DNA species in embalmed tissue (Gielda et al.,
2017). However, due to the sensitivity of RNA to heat (Opitz et al., 2010), the heat extraction step
was eliminated from our extraction procedure and replaced with an overnight proteinase K
incubation. While this may result in RNA degradation, previous studies have demonstrated that
gene expression analysis can still be performed with RNA that is partially degraded, although
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certain genes were found to be affected by RNA degradation, thereby excluding their utilization
in genomic studies (Opitz et al., 2010).
Microarray analysis of RNA from cadaveric hearts revealed that RNA transcript yield
varied depending on the sample, indicating that improvements to the protocol are necessary for
enhanced consistency, although some degradation is inevitable due to variable conditions during
the postmortem interval between death and fixation. Numerous studies have demonstrated that
mRNAs are stable for periods of up to 48 hours post-mortem (Barton et al., 1993; Leonard et al.,
1993; Schramm et al., 1999; Bahn et al., 2001; Lee et al., 2013; White et al., 2018), although other
factors such as pH (Kingsbury et al., 1995) and temperature (Lee et al., 2013) have been found to
significantly influence RNA stability. Studies by Jewell et al demonstrated that RNA from human
lung tissue was stable for up to 5 hours at room temperature (2002) and recent studies comparing
RNA integrity at 3 hour and 24 hour time points after tissue removal revealed that mRNA remained
stable at the 3 hour time point even at room temperature. It was noted, though, that there was a
decrease in RNA integrity at 24 hours at room temperature compared to 24 hours on ice (Lee et
al., 2013). However, since many anatomical donation programs require that the donor be placed
at 4°C within 4 hours of death and embalming occurs within 24 hours of death (Virginia
Department of Health, 2020), postmortem interval may not be the sole reason for RNA degradation
observed in this study, but rather it could be due to the prolonged exposure to embalming fluids.
Therefore, degradation may be minimized by improvements to extraction protocols.
Certain forensic studies have confirmed this concept, displaying detection of transcripts
even from individuals possessing a 7-day post-mortem interval.

However, comparison of

amplification success between samples stored at -80ºC and those stored at room temperature as
FFPE blocks revealed significant differences. Certain transcripts were undetectable beyond a 3-
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day postmortem interval in samples stored as FFPE blocks, while the same transcripts could be
detected after a 7-day postmortem interval in frozen samples (Hansen et al., 2014). This suggests
that it is not the post-mortem interval that primarily affects RNA integrity, but rather the difficulties
in extracting RNA from formalin-fixed tissue. Therefore, the degradation occurring postmortem
is not the primary hurdle that must be overcome in working with cadaveric tissue, but rather the
unique challenges of extracting intact RNA from embalmed tissue.
Nevertheless, despite the degradation observed in our samples, our analysis of 13 cadaveric
donor hearts revealed that 11,342 unique transcripts were detected in at least one of the 13 samples,
although the highest number of transcripts detected in a single sample was 10,344. Out of these
11,342 transcripts, 6,561 were consistently detected in all 13 cadaveric samples regardless of any
variations that may have existed in timeline or procedures, making these transcripts particularly
viable candidates for future cadaveric studies. Since 14,409 genes make up the heart-specific
transcriptome (The Human Protein Atlas, n.d.), these results indicate that there were 3,067
transcripts lost between all 13 samples, but that the variability detected between samples was
significant, with only 45% of the genes comprising the heart-specific transcriptome being
consistently detected in all samples. However, it was noted that for two samples submitted for
microarray, cDNA gels revealed differing ranges of transcript size and that the cDNA sample
reflecting higher molecular weight fragments was correlated with the highest individual transcript
yield between all 13 samples (data not shown). cDNA gels were not run for all 13 samples, but it
is likely that cDNA gel comparisons could serve as a potential method for selecting the highest
quality samples for microarray analysis.
Although analysis of differentially expressed genes only took into account the 6,561
transcripts detected in all 13 samples, differential expression of heart disease risk factors was
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observed in both diagnosed and undiagnosed sample groups. These results are tentative due to the
fact that only one control sample was available, but assessment of genes meeting the criteria of a
fold change greater than 2 and a one sample t-test p-value of <0.05 revealed a number of heart
disease-related risk factors. Diagnosed CVD samples possessed 11 differentially expressed genes
associated with heart disease compared with the control and 16 heart disease-associated genes
were differentially expressed in undiagnosed CVD samples.
Due to the heart-specific nature of this study, analysis of differential gene expression was
localized to genes associated with different forms of heart disease including cardiac arrhythmias,
cardiomyopathies, and myocardial infarction. Differential gene expression was also noted in
additional genes associated with vascular forms of CVD, but these genetic risk factors were not
included in our analysis. Future work will investigate the differential expression of CVD risk
factors beyond those associated with the development of heart disease.
Differential gene expression between diagnosed CVD and undiagnosed CVD samples
displayed distinct patterns of gene expression resulting in clustering of diagnosed CVD samples
separately from undiagnosed CVD samples. Particularly noteworthy was the fact that the one
undiagnosed CVD sample possessing a documented condition with possible CVD causation—
donor 8—clearly clustered with diagnosed CVD samples, suggesting that this sample would be
more accurately classified as a sample possessing CVD. These results suggest that diagnosed
CVD samples possess distinct gene expression profiles distinguishing them from those lacking
diagnosed CVD. These comparisons may serve as a means of identifying individuals with
undiagnosed CVD based on how their gene expression profiles align with those of diagnosed CVD
samples.
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Conclusion
This study is the first to demonstrate successful extraction of amplifiable RNA from
embalmed human cadaveric donors for the purpose of identifying genetic risk factors for heart
disease. These findings indicate that genetic components may exist for many cases of heart disease
observed in cadaveric donors, both for individuals with documented and those with undocumented
CVD. Since many of these genetic risk factors may have been unknown and inherited by family
members, it is important that genetic risk be identified and confirmed within these donors. Family
members can then be informed of their potential risk and appropriate prevention and treatment
strategies can be implemented. Establishment of communication channels between gross anatomy
labs and anatomical donor programs should be pursued in order to inform family members of
genetic risk as these conditions are encountered and identified within the gross anatomy lab.

Limitations
By far the most significant limitation in this study was the presence of a single control for
comparisons between diseased and normal groups. Based on the fact that only 1 control sample
was available, it is difficult to determine whether variations observed between normal and diseased
samples are due to natural differences between cadaveric donors or whether it is in fact due to
differential expression of genetic risk factors.
It is also possible that significant genetic risk factors could have been missed due to fact
that gene comparisons were based on overall differential expression as indicated by the average of
the diseased sample intensities. Since these donors manifested with different types of CVD, it is
not guaranteed that all donors would display the same patterns of differential expression, making
it possible that one or more samples lacking genetic risk factors could obscure significant results.
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An additional limitation was the fact that documentation for one of the six samples in the
undiagnosed CVD class did include a non-traumatic cerebral hemorrhage, which may or may not
be due to CVD-related causes. Based on hierarchical clustering analysis, it is likely that the
cerebral hemorrhage in donor 8 did have CVD causation due to its clear clustering with diagnosed
CVD samples. If this individual’s cerebral hemorrhage was due to CVD, this sample may be better
classified with the diagnosed CVD samples and its presence within the undiagnosed CVD sample
group may skew results.
Finally, this study was also limited by the lack of qPCR confirmations. In order to
conclusively establish the differential expression of genetic risk factors, follow-up studies should
be performed to establish correlations between microarray analysis and differential expression
determined by qPCR.
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CHAPTER 4

Conclusions and Future Directions

108

Conclusions
The work outlined in this study demonstrates the significant prevalence of undiagnosed
heart disease in cadaveric donors and proposes genomic studies utilizing embalmed tissue as a
means of identifying genetic risk factors associated with heart disease.

Significance of Undocumented Heart Disease
In chapter 1, I outline the potential for undiagnosed heart disease based on the following
factors: atypical or non-specific presentation of symptoms (Quinn et al., 2017; Reynolds et al.,
2019), the presence of comorbidities in the elderly (Torabi et al., 2009; Fares et al., 2011b), and
misdiagnoses in the female population due to manifestations that may deviate from the welldefined features of disease progression in males (McSweeney et al., 2003; Hsich and Piña, 2009;
Mazure et al., 2015). In addition, many cases of heart disease may remain unknown even after
death due to the significant underutilization of autopsy examination, particularly in elderly and
female individuals (Tai et al., 2001; Attems et al., 2004; Hoyert, 2011; Friberg et al., 2019). There
have been numerous studies describing identification of undiagnosed heart disease following
autopsy examination (Sington et al., 2002; Ravakhah, 2006; Mieno et al., 2016; Friberg et al.,
2019), but there remains a level of uncertainty regarding the extent to which these findings apply
to the population as a whole—specifically to those who will never receive an autopsy following
death (Shojania et al., 2008; Tavora et al., 2008a).
In order to identify the prevalence of undiagnosed heart disease in the absence of autopsy
examination, I have proposed the utilization of cadaveric donors due to the fact that these
individuals do not receive an autopsy after death and therefore should be closely representative of
the non-autopsied population. Numerous studies have outlined the presence of pathology in
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cadaveric donors and their viability as a means of gross, histologic, and genomic study of disease
(Nicholson et al., 2005; Chun et al., 2007; Wood et al., 2010; Gerhard et al., 2016; Gielda et al.,
2017; Plummer et al., 2018; Rae et al., 2018). However, past studies have not examined the
prevalence of undocumented heart disease in the cadaveric population, and specifically how this
may vary between male and female donors. Furthermore, while these studies have demonstrated
successful utilization of cadaveric tissue for DNA analysis (Gerhard et al., 2016; Gielda et al.,
2017), there are currently no studies which have successfully extracted amplifiable RNA from
cadaveric tissue for the purpose of gene expression analysis and detection of high-risk genetic
variants associated with heart disease.

Prevalence of Undocumented Heart Disease
In chapter 2, I present my findings regarding the extensive prevalence of undocumented
heart disease within the cadaveric population. These results demonstrated that while only 56% of
cadaveric donors possess documented CVD, and only 30% possess documented heart disease,
gross examination revealed features consistent with mild to severe heart disease in nearly all of
the remaining donors, resulting in a total prevalence of heart disease which may be as high as 98%.
It was also found that heart disease was more likely to be undocumented within the female
population, with medical records for female donors revealing significantly lower numbers of
documented heart conditions than male donors, but gross examination revealing a similar overall
prevalence between male and female donors. Whereas 50% of male donors possessed documented
heart disease compared with only 11% of female donors, total prevalence of heart disease based
on both documented and undocumented cases was 100% in male donors and 96% in female donors.
This indicates that prevalence of heart disease may be comparable between male and female
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donors, but that heart disease is significantly underdiagnosed in females.
These studies also revealed that while undocumented heart disease did not vary based on
age in male donors, younger female donors were more likely to possess undocumented heart
disease, suggesting that undocumented heart disease may be particularly prevalent in the younger
sector of the elderly female population. Since the majority of these donors were elderly, it is
unknown how closely these findings correlate with the middle-aged female population, but
suggests that within the elderly population, heart disease is less likely to be documented in younger
females. Further investigation is warranted regarding the extent of undocumented heart disease
for females in other age groups.

Extraction of Amplifiable RNA from Cadaveric Heart Tissue
Finally, in chapter 3, I outline a modified protocol for the extraction of amplifiable RNA
from formalin-fixed cadaveric heart tissue. This provides a means of bridging the gap between
the detection of undocumented disease in cadaveric donors and correlation with changes to gene
expression. This connection previously could not be made due to the lack of any protocol for
extracting amplifiable RNA from cadaveric tissue.
These results demonstrated the successful amplification of both GAPDH and cTnT from
cadaveric tissue, but also demonstrated the presence of genomic DNA contamination in certain
samples and minimal success in amplifying the housekeeping gene β-actin. This suggests the need
for further modifications to the protocol in order to ensure more consistent quality and
amplification of extracted RNA.
Nevertheless, these findings demonstrate that RNA extracted from embalmed cadaveric
donors can be utilized for gene expression studies and that many transcripts related to heart disease
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can be detected through microarray analysis. This provides an exciting avenue by which gross
pathologic findings revealed in cadaveric dissection can be correlated with genetic risk factors for
those conditions. The effects of these differentially expressed genes can likewise be correlated
with changes observed in the cellular structure of the tissue through histologic analysis, providing
a comprehensive means of studying the interaction between genetic risk factors and histologic
structure. These findings can further be related to manifestation of these features on a gross scale
and their connection to other co-existing pathologies.
Collectively, the ability to study disease on a gross, histologic, and genomic level within
the context of cadaveric donor dissection provides a valuable opportunity to comprehensively
study the features and manifestations of heart disease. This information can be utilized to broaden
our understanding of heart disease in the hopes of facilitating more accurate detection and
intervention, thereby reducing the destructive effects of heart disease in the population.

Future Directions
Confirmation of genetic risk factors for heart disease
Building off our preliminary findings from microarray analysis, future work will analyze
these results in more detail to determine genetic risk factors that are significantly up- or downregulated in specific cadavers with diagnosed and undiagnosed CVD. Further collection of control
hearts will also be performed in order to allow for more accurate comparisons between diseased
and normal heart tissue.
In addition, while differential expression appeared to be present based on preliminary
work, future work should include qPCR confirmations. These experiments can be utilized to
confirm genetic risk factors which appear to be differentially expressed within donors possessing
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heart disease and to determine the extent to which microarray noise may have skewed our results
(Chuaqui et al., 2002). qPCR has not been done utilizing embalmed human cadaveric tissue
before, and so future work will seek to develop successful protocols for qPCR in cadaveric tissue.

RNA extraction from additional cadaveric organs
In addition to RNA extraction from heart tissue, our studies also examined and compared
the extraction and amplification success of RNA from other cadaveric organs isolated from 4
different donors. RNA extracted from formalin-fixed brain, heart, kidney, liver, skeletal muscle,
and pancreas confirmed successful extraction of RNA in these 6 organs, but with varying yield
and purity levels. Brain tissue produced the lowest RNA yield at an average of 105.88 ng/µl, as
well as the lowest 260/280 ratio at an average of 1.68. However, of the 4 cadaveric donors
assessed, all 4 brain RNA samples displayed successful amplification of GAPDH. Extraction of
RNA from heart and skeletal muscle also displayed successful amplification of GAPDH in 100%
of donors, with average yields of 182.18 ng/µl and 195.38 ng/µl and average 260/280 absorbance
of 1.75 and 1.70 for heart and skeletal muscle, respectively. GAPDH was successfully amplified
in 75% of samples for kidney and pancreatic tissue, with an average yield of 358.9 ng/µl and a
260/280 ratio of 1.74 for kidney, and with pancreatic tissue possessing the highest average yield
and purity at 1018.78 ng/µl and 1.86. Liver possessed an average yield of 358.9 ng/µl and 260/280
ratio of 1.74, but displayed the lowest rate of GAPDH amplification, with only 50% of samples
producing amplifiable RNA (Table 4.1).
Analysis of GAPDH amplification between cadaveric donors revealed that certain donors
displayed stronger amplification than others, suggesting that fixation timeline or extraction success
may have differed between cadavers. Therefore, certain donors may serve as better candidates for
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Tissue

Yield (ng/µl)

260/280

260/230

GAPDH
Amplification

Brain

105.88 (± 41.87)

1.68 (± 0.04)

0.28 (±0.11)

100%

Heart

182.18 (± 51.74)

1.75 (± 0.10)

0.70 (± 0.33)

100%

Kidney

358.9 (± 227.13)

1.74 (± 0.12)

0.73 (± 0.44)

75%

Liver

619.25 (± 481.29)

1.85 (± 0.13)

1.30 (± 0.39)

50%

Skeletal Muscle

195.38 (± 98.88)

1.70 (± 0.10)

0.39 (± 0.11)

100%

Pancreas

1018.78 (± 254.21)

1.86 (± 0.07)

1.52 (± 0.85)

75%

Table 4.1: Average quantification and absorbance ratios for RNA obtained from 6 organs
in 4 different cadaveric donors.
Isolation of RNA from a selection of organs in 4 distinct cadaveric donors revealed variable
yield and purity between samples, but successful amplification of GAPDH was observed in at
least 2 of the 4 donors for all organs, and most tissues displayed higher rates of amplification.
Brain, heart, and skeletal muscle displayed the most consistent amplification rates, with all 4
cadaveric donors yielding successful amplification in these tissues. While GAPDH did not
display successful amplification in all donors for kidney, liver, and pancreas samples, these
tissues nevertheless displayed high average yield and purity, and could be successfully
amplified in select cadaveric donors. This suggests that failure to amplify GAPDH in specific
donors could be due to disease states, fixation variables, and other factors which could not be
controlled.
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Figure 4.1 RT-PCR of GAPDH visualized by 1% agarose gel electrophoresis in 6 organs
extracted from 4 cadaveric donors.
GAPDH amplification revealed successful amplification in all brain samples (B1A, B1B, B2,
B3, and B4), all heart samples (H1, H2, H3, and H4), and all skeletal muscle samples (M1,
M2, M3. and M4). GAPDH amplification in kidney and pancreas revealed successful
amplification in 75% of samples (K2, K3, and K4 for kidney and P1, P2, and P4 for pancreas).
GAPDH amplification of liver RNA revealed a 50% amplification rate, with only L1 and L4
displaying successful GAPDH amplification. Bands depicting a fragment size of 295bp and
204bp indicated genomic DNA contamination. The 204bp genomic DNA fragment may have
partially obscured the 205bp product, but the minimal presence of genomic DNA
contamination at the 295bp level in most samples indicates that a strong 205bp band is
primarily due to amplification of the GAPDH transcript rather than genomic DNA
contamination.
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gene expression analysis than others (Figure 4.1). Disease state could also influence success of
RNA extraction and amplification since it was observed that the one kidney sample which did not
yield amplifiable RNA (K1) was taken from an organ possessing calcification which likely
hindered the extraction process. Future analysis of RNA yield should take into account disease
states of different organs as this may influence the quantity and purity of extracted RNA.

Differential expression of lncRNAs in heart disease
Beyond protein-coding genes, past studies have revealed that the human genome also
encodes ~16,000 unique lncRNAs (Sun et al., 2018). While the focus of this study emphasized
protein-coding genes, microarray analysis of the 13 cadaveric heart samples also indicated
successful detection of 14,511 unique lncRNAs between the 13 cadaveric samples. Recent studies
have demonstrated the critical role that lncRNAs may play in the pathophysiology of heart disease,
making them promising targets for future studies (Sun and Wang, 2019, Chen et al., 2019).

Immunohistochemistry to correlate genetic risk factors with structural changes
Based on genetic findings observed in the heart tissue of these donors, future studies will
also pursue immunohistochemistry (IHC) analysis of structural changes to the heart tissue
associated with genetic risk factors. Past studies have expressed concern regarding the use of
formalin-fixed tissue for the purpose of IHC studies since interactions within the tissue may block
antigens and prevent antibody recognition (Werner et al., 2000; Arnold et al., 2009; Eltoum et al.,
2013). However, studies by Webster et al have demonstrated that while formalin-fixation may
impair recognition for select antigens, past studies were limited in the sense that only a few select
antigens were evaluated (2009). They demonstrated that out of a total of 61 antigens, only 3
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displayed diminished detection after prolonged fixation, while the remaining 58 antigens could be
detected by IHC even after a 7-week fixation period. Later studies have likewise revealed success
in the utilization of formalin-fixed cadaveric tissue for IHC analysis (Jensen et al., 2011).
Preliminary studies of our own in control heart tissue have confirmed these results,
demonstrating reliable preservation and structural integrity of cadaveric tissue which can be
successfully used for IHC analysis (Figure 4.3). These methods will be utilized to identify
structural changes within the heart tissue which are correlated with differential gene expression.
The integration of IHC analysis with the genetic findings from microarray analysis will potentially
provide a means by which the progression and manifestations of disease can be studied within the
cadaveric population.

Communication of undocumented findings to donor family members
Based on our findings regarding undiagnosed conditions with genetic components, future
work will also seek to establish routes of communication with donor facilities by which these
unknown findings can be relayed to affected family members. Past studies in cadaveric donors
have recognized the need for communication channels between dissection facilities and donor
families based on the discovery of undocumented disease (Plummer et al., 2018), and our studies
have confirmed the need for this relationship specifically regarding undocumented heart disease.
Reports have documented significant success in reducing risk of heart disease by simple
modifications to lifestyle risk factors (Mozaffarian et al., 2008), but in order to facilitate early
intervention and treatment, donor family members must be made aware of their risk for developing
heart disease. Otherwise, they too may develop these life-threatening conditions, thus perpetuating
the cycle of heart disease-related disability and death.
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Figure 4.2 Immunofluorescent imaging of cardiac muscle tissue extracted from control
cadaveric heart tissue.
IHC analysis of a control cadaveric donor heart demonstrated structural integrity of
cardiomyocytes and surrounding architecture, confirming gross observations and
demonstrating the reliability of cadaveric heart tissue for IHC studies.
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